k141_34397_14	SARG|gi|542061059|gb|ERI11611.1|	35.0	217	297	316	7.51e-34	124
k141_34397_14	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	32.9	246	297	293	1.84e-32	120
k141_34397_14	SARG|gi|500194536|ref|WP_011867743.1|	35.9	220	297	306	6.54e-32	119
k141_34397_14	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.0	216	297	307	7.05e-26	103
k141_34397_14	SARG|gi|171851258|emb|CAQ04234.1|	37.9	58	297	483	6.56e-06	46.2
k141_34397_20	SARG|gi|640235983|ref|WP_024832225.1|	33.8	397	440	404	2.18e-71	229
k141_34397_20	SARG|gi|496675169|ref|WP_009317659.1|	33.0	397	440	405	9.54e-70	225
k141_34397_20	SARG|gi|495112610|ref|WP_007837430.1|	33.0	397	440	405	1.89e-69	224
k141_34397_20	SARG|CAJ45367	34.5	391	440	405	3.73e-69	224
k141_34397_20	SARG|gi|1028096845|ref|WP_063853563.1|	34.5	391	440	405	3.73e-69	224
k141_34397_20	SARG|AAY68306	34.0	397	440	405	5.25e-69	223
k141_34397_20	SARG|gi|748788175|ref|WP_040036560.1|	32.7	397	440	405	7.38e-69	223
k141_34397_20	SARG|YP_001396002	32.7	397	440	408	7.99e-69	223
k141_34397_20	SARG|gi|727676799|ref|WP_033826817.1|	32.7	397	440	408	7.99e-69	223
k141_34397_20	SARG|gi|517493838|ref|WP_018664415.1|	32.7	397	440	408	7.99e-69	223
k141_34459_30	SARG|gi|542061059|gb|ERI11611.1|	38.1	310	317	316	2.54e-66	209
k141_34459_30	SARG|gi|488120365|ref|WP_002191762.1|	38.2	309	317	309	4.63e-65	206
k141_34459_30	SARG|gi|487936534|ref|WP_002010000.1|	37.3	311	317	309	2.60e-64	204
k141_34459_30	SARG|gi|895808656|emb|COR83787.1|	36.7	308	317	309	3.67e-64	204
k141_34459_30	SARG|gi|895736250|emb|COF64653.1|	36.7	308	317	309	5.18e-64	203
k141_34459_30	SARG|gi|488053456|ref|WP_002124853.1|	37.3	311	317	309	5.18e-64	203
k141_34459_30	SARG|gi|507055561|ref|WP_016126482.1|	37.3	311	317	309	7.31e-64	203
k141_34459_30	SARG|gi|445996710|ref|WP_000074565.1|	36.7	308	317	309	7.31e-64	203
k141_34459_30	SARG|gi|488067981|ref|WP_002139378.1|	37.5	309	317	309	1.03e-63	202
k141_34459_30	SARG|gi|488068784|ref|WP_002140181.1|	37.2	309	317	309	1.03e-63	202
k141_34459_31	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.2	235	244	228	2.62e-41	140
k141_34459_31	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.8	237	244	231	1.13e-40	138
k141_34459_31	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.2	239	244	247	1.62e-37	130
k141_34459_31	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	33.3	237	244	239	7.33e-37	129
k141_34459_31	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.4	238	244	229	1.12e-36	128
k141_34459_31	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	31.5	238	244	235	6.13e-34	121
k141_34459_31	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.8	235	244	219	1.24e-32	117
k141_34459_31	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.6	241	244	225	2.03e-32	117
k141_34459_31	CARD|gb|AAC73788.1|ARO:3003841|kdpE	33.6	241	244	225	2.03e-32	117
k141_34459_31	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.8	234	244	231	2.54e-31	114
k141_34459_42	SARG|gi|686172137|ref|WP_031795999.1|	20.8	432	474	451	3.30e-09	57.8
k141_34459_42	SARG|gi|1006223553|ref|WP_061745579.1|	20.9	392	474	451	3.30e-09	57.8
k141_34459_42	SARG|gi|686355454|ref|WP_031890196.1|	21.2	392	474	451	5.79e-09	57.0
k141_34459_42	SARG|gi|487138435|ref|WP_001629863.1|	20.9	388	474	451	5.79e-09	57.0
k141_34459_42	SARG|gi|446573689|ref|WP_000651035.1|	21.9	393	474	451	7.67e-09	56.6
k141_34459_42	SARG|gi|516415429|ref|WP_017804827.1|	21.9	393	474	451	7.67e-09	56.6
k141_34459_42	SARG|gi|686367913|ref|WP_031894914.1|	21.2	392	474	451	1.02e-08	56.2
k141_34459_42	SARG|gi|686309068|ref|WP_031870147.1|	21.2	392	474	451	1.02e-08	56.2
k141_34459_42	SARG|gi|686320684|ref|WP_031875798.1|	21.2	392	474	451	1.02e-08	56.2
k141_34459_42	SARG|gi|686123390|ref|WP_031769354.1|	21.9	393	474	451	1.35e-08	55.8
k141_34459_49	SARG|gb|CAA03986.1|ARO:3000343|tap	35.7	157	202	409	4.89e-21	88.6
k141_25907_14	SARG|ABV82118	25.1	451	602	639	7.80e-27	114
k141_25907_14	megares|MEG_7171|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.1	438	602	639	7.80e-27	114
k141_25907_14	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.4	438	602	629	1.00e-26	114
k141_25907_14	ResF|tet(O/W)_4_AM889121_1	27.4	438	602	639	1.04e-26	114
k141_25907_14	megares|MEG_7177|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	439	602	639	1.04e-26	114
k141_25907_14	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	26.0	439	602	639	1.38e-26	113
k141_25907_14	SARG|ABF69686	26.0	439	602	639	1.38e-26	113
k141_25907_14	SARG|ABG81258	26.0	439	602	639	1.38e-26	113
k141_25907_14	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.4	438	602	629	1.78e-26	113
k141_25907_14	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.4	438	602	629	1.78e-26	113
k141_25907_31	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	47.3	226	233	232	3.51e-70	213
k141_25907_31	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	47.3	226	233	232	3.51e-70	213
k141_25907_31	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.8	226	233	231	6.72e-65	200
k141_25907_31	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	43.4	226	233	231	9.52e-65	199
k141_25907_31	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.4	226	233	231	9.52e-65	199
k141_25907_31	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.4	226	233	231	7.68e-64	197
k141_25907_31	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.5	226	233	231	1.09e-63	197
k141_25907_31	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	42.3	234	233	239	4.51e-62	193
k141_25907_31	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.0	231	233	235	3.22e-61	191
k141_25907_31	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.1	228	233	233	1.39e-59	186
k141_25907_32	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	44.1	306	385	392	9.56e-81	251
k141_25907_32	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	43.2	303	385	386	1.13e-80	251
k141_25907_32	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	43.2	303	385	386	1.13e-80	251
k141_25907_32	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	43.9	303	385	384	1.68e-79	248
k141_25907_32	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	43.9	303	385	384	1.68e-79	248
k141_25907_32	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	43.8	297	385	386	1.78e-79	248
k141_25907_32	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	43.8	297	385	386	1.78e-79	248
k141_25907_32	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	43.4	297	385	388	1.06e-78	246
k141_25907_32	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	43.4	297	385	388	1.06e-78	246
k141_25907_32	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	43.8	297	385	382	1.26e-78	246
k141_17401_7	SARG|gi|639216333|ref|WP_024554080.1|	48.7	232	239	648	1.41e-69	224
k141_17401_7	SARG|gi|742378414|ref|WP_038857601.1|	48.7	232	239	647	3.80e-69	223
k141_17401_7	SARG|gi|495004199|ref|WP_007730213.1|	49.1	234	239	647	5.32e-69	222
k141_17401_7	SARG|gi|896325272|ref|WP_049294291.1|	48.3	232	239	648	1.49e-68	221
k141_17401_7	SARG|gi|696411918|ref|WP_032982657.1|	47.2	235	239	647	2.05e-68	221
k141_17401_7	SARG|gi|696402390|ref|WP_032974230.1|	47.2	235	239	647	2.86e-68	220
k141_17401_7	SARG|gi|696423952|ref|WP_032993748.1|	47.2	235	239	647	2.86e-68	220
k141_17401_7	SARG|gi|742409107|ref|WP_038888226.1|	48.7	234	239	647	4.01e-68	220
k141_17401_7	SARG|gi|657888313|ref|WP_029592374.1|	48.7	228	239	648	5.71e-68	219
k141_17401_7	SARG|gi|639225329|ref|WP_024561799.1|	48.7	228	239	648	5.71e-68	219
k141_17401_8	SARG|gi|694073280|ref|WP_032419142.1|	32.4	398	398	646	2.43e-48	172
k141_17401_8	SARG|gi|647265102|ref|WP_025712979.1|	32.4	398	398	646	2.43e-48	172
k141_17401_8	SARG|gi|1031836330|ref|WP_064161764.1|	32.4	398	398	646	3.36e-48	172
k141_17401_8	SARG|gi|895895864|ref|WP_048997630.1|	31.7	398	398	644	4.53e-48	172
k141_17401_8	SARG|gi|1043941253|emb|SBY03087.1|	32.2	398	398	646	4.63e-48	172
k141_17401_8	SARG|gi|1031873672|ref|WP_064188664.1|	32.2	398	398	646	4.63e-48	172
k141_17401_8	SARG|gi|782700886|ref|WP_045611431.1|	32.2	398	398	646	4.63e-48	172
k141_17401_8	SARG|gi|951351507|ref|WP_057729122.1|	32.2	398	398	646	6.39e-48	171
k141_17401_8	SARG|gi|556476567|ref|WP_023328168.1|	32.2	398	398	641	8.34e-48	171
k141_17401_8	SARG|gi|694088163|ref|WP_032432902.1|	32.2	398	398	646	8.82e-48	171
k141_38993_15	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	32.5	234	298	346	6.98e-21	90.1
k141_38993_19	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	25.8	360	634	593	3.28e-14	74.7
k141_38993_21	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	31.7	502	495	481	1.76e-56	194
k141_38993_21	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	31.2	490	495	451	2.60e-54	187
k141_38993_21	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	30.4	490	495	451	1.96e-51	180
k141_30423_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	53.0	251	280	255	4.37e-91	269
k141_30423_2	SARG|gi|643601187|ref|WP_025237288.1|	39.5	220	280	648	1.44e-44	158
k141_30423_2	SARG|gi|974628291|ref|WP_059215695.1|	39.5	220	280	648	1.44e-44	158
k141_30423_2	SARG|gi|446110298|ref|WP_000188153.1|	39.5	220	280	648	1.44e-44	158
k141_30423_2	SARG|gi|974633183|ref|WP_059219858.1|	39.5	220	280	648	1.44e-44	158
k141_30423_2	SARG|gi|974684692|ref|WP_059267998.1|	39.5	220	280	648	1.44e-44	158
k141_30423_2	SARG|gi|1035686596|ref|WP_064530178.1|	40.0	220	280	648	1.99e-44	158
k141_30423_2	SARG|gi|693054987|ref|WP_032223114.1|	39.5	220	280	648	2.74e-44	157
k141_30423_2	SARG|gi|974652669|ref|WP_059238406.1|	39.5	220	280	648	2.74e-44	157
k141_30423_2	SARG|gi|510923671|ref|WP_016244456.1|	39.5	220	280	648	2.74e-44	157
k141_30423_3	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	35.4	285	343	341	2.21e-46	159
k141_30423_4	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	42.2	223	223	223	1.51e-56	178
k141_30423_4	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.9	218	223	229	8.44e-37	127
k141_30423_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	31.3	227	223	231	3.01e-34	121
k141_30423_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.3	227	223	231	3.01e-34	121
k141_30423_4	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	30.1	226	223	231	8.40e-34	120
k141_30423_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	30.7	228	223	232	4.75e-33	118
k141_30423_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	30.7	228	223	232	4.75e-33	118
k141_30423_4	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	30.7	228	223	230	8.96e-33	117
k141_30423_4	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	29.2	226	223	231	1.82e-32	116
k141_30423_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.8	222	223	231	7.74e-31	112
k141_13510_24	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	47.8	159	157	159	1.13e-42	138
k141_9273_11	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.4	869	860	1024	2.49e-32	134
k141_9273_11	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.4	869	860	1024	2.49e-32	134
k141_9273_11	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.3	869	860	1024	1.31e-31	132
k141_9273_11	SARG|gb|CAA53189|ARO:3000521|mupA	22.3	869	860	1024	1.31e-31	132
k141_9273_11	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	22.4	863	860	1107	5.14e-17	85.1
k141_9273_11	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	22.4	863	860	1107	5.14e-17	85.1
k141_13676_7	SARG|gi|313614636|gb|EFR88215.1|	25.1	398	494	453	1.39e-27	114
k141_13676_7	SARG|gi|313638554|gb|EFS03703.1|	24.6	406	494	453	1.57e-26	110
k141_13676_7	SARG|gi|984518628|emb|CUM21384.1|	25.2	322	494	341	1.51e-25	106
k141_13676_7	SARG|gi|313619623|gb|EFR91268.1|	25.6	215	494	237	1.81e-16	77.8
k141_13676_7	SARG|gi|313609598|gb|EFR85124.1|	26.0	215	494	226	2.02e-16	77.4
k141_13676_7	SARG|HE999704.1.gene1125.p01	33.3	87	494	107	1.17e-06	46.2
k141_13676_19	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	29.1	779	949	1024	1.13e-106	353
k141_13676_19	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	29.1	779	949	1024	1.13e-106	353
k141_13676_19	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	29.1	779	949	1024	1.13e-106	353
k141_13676_19	SARG|gb|CAA53189|ARO:3000521|mupA	29.1	779	949	1024	1.13e-106	353
k141_13676_19	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	27.4	950	949	1107	6.24e-84	292
k141_13676_19	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	27.4	950	949	1107	6.24e-84	292
k141_5505_28	SARG|gb|APB03219.1|ARO:3003986|TaeA	24.9	233	265	648	6.35e-11	61.2
k141_5505_35	SARG|gi|542061059|gb|ERI11611.1|	38.3	206	294	316	1.07e-38	137
k141_5505_35	SARG|gi|488053456|ref|WP_002124853.1|	38.3	206	294	309	9.70e-38	134
k141_5505_35	SARG|gi|488130770|ref|WP_002201978.1|	38.3	206	294	309	9.70e-38	134
k141_5505_35	SARG|gi|507055561|ref|WP_016126482.1|	38.3	206	294	309	1.36e-37	134
k141_5505_35	SARG|gi|507044560|ref|WP_016115614.1|	36.7	210	294	306	2.49e-37	133
k141_5505_35	SARG|gi|488067981|ref|WP_002139378.1|	37.9	206	294	309	2.67e-37	133
k141_5505_35	SARG|gi|487936534|ref|WP_002010000.1|	37.9	206	294	309	2.67e-37	133
k141_5505_35	SARG|gi|447057509|ref|WP_001134765.1|	37.9	206	294	309	5.23e-37	132
k141_5505_35	SARG|P42332	37.9	206	294	306	6.85e-37	132
k141_5505_35	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	37.9	206	294	306	6.85e-37	132
k141_48076_9	SARG|gi|445996710|ref|WP_000074565.1|	36.4	225	301	309	6.47e-42	145
k141_48076_9	SARG|gi|445996719|ref|WP_000074574.1|	36.0	225	301	309	1.28e-41	145
k141_48076_9	SARG|P42332	35.2	236	301	306	2.34e-41	144
k141_48076_9	SARG|ABB80128	34.9	238	301	306	2.34e-41	144
k141_48076_9	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	35.2	236	301	306	2.34e-41	144
k141_48076_9	SARG|gi|510143239|gb|AGN36970.1|	35.2	236	301	313	2.76e-41	144
k141_48076_9	SARG|gi|895736250|emb|COF64653.1|	36.0	225	301	309	3.52e-41	144
k141_48076_9	SARG|gi|446110087|ref|WP_000187942.1|	36.0	225	301	309	3.52e-41	144
k141_48076_9	SARG|gi|445996714|ref|WP_000074569.1|	36.0	225	301	309	4.94e-41	143
k141_48076_9	SARG|ZP_04081918	36.2	224	301	306	6.46e-41	143
k141_48076_50	SARG|gb|AAC75089.1|ARO:3003577|ugd	57.6	99	100	388	1.85e-35	123
k141_48076_65	SARG|gi|851913025|ref|WP_048215946.1|	35.3	235	259	648	1.42e-35	132
k141_48076_65	SARG|YP_002850060	35.3	235	259	648	1.42e-35	132
k141_48076_65	SARG|gi|489930965|ref|WP_003834285.1|	35.3	235	259	648	1.42e-35	132
k141_48076_65	SARG|gi|992380339|ref|WP_061067665.1|	35.3	235	259	648	1.42e-35	132
k141_48076_65	SARG|gi|696368937|ref|WP_032943949.1|	35.5	234	259	648	1.95e-35	132
k141_48076_65	SARG|gi|949718947|ref|WP_057063453.1|	35.3	235	259	648	1.95e-35	132
k141_48076_65	SARG|gi|489936909|ref|WP_003840216.1|	35.3	235	259	648	1.95e-35	132
k141_48076_65	SARG|gi|507079862|ref|WP_016150620.1|	35.3	235	259	648	1.95e-35	132
k141_48076_65	SARG|gi|949791377|ref|WP_057104572.1|	35.3	235	259	648	1.95e-35	132
k141_48076_65	SARG|gi|696361545|ref|WP_032936694.1|	35.5	234	259	648	2.67e-35	132
k141_31470_5	SARG|gi|514904648|ref|WP_016630030.1|	27.7	184	494	498	1.26e-09	59.3
k141_31470_5	SARG|gi|498528849|ref|WP_010828356.1|	27.2	184	494	498	3.86e-09	57.8
k141_31470_5	SARG|gi|881017353|ref|WP_048737885.1|	27.2	184	494	498	6.75e-09	57.0
k141_31470_5	SARG|gi|498521217|ref|WP_010821069.1|	27.2	184	494	498	6.75e-09	57.0
k141_31470_5	SARG|gi|514883218|ref|WP_016615053.1|	27.2	184	494	498	6.75e-09	57.0
k141_31470_5	SARG|gi|1046366091|gb|OCK16447.1|	27.2	184	494	498	6.75e-09	57.0
k141_31470_5	SARG|gi|488303094|ref|WP_002374069.1|	27.2	184	494	498	6.75e-09	57.0
k141_31470_5	SARG|gi|488319039|ref|WP_002388424.1|	27.2	184	494	498	6.75e-09	57.0
k141_31470_5	SARG|ZP_04437889	27.2	184	494	498	6.75e-09	57.0
k141_31470_5	SARG|gi|498397181|ref|WP_010710665.1|	27.2	184	494	498	6.75e-09	57.0
k141_31470_6	megares|MEG_7331|Drugs|Glycopeptide|VanA-type_resistance_protein|VAN_1	54.2	48	325	114	3.06e-09	53.1
k141_31470_6	CARD|gb|AAO82019.1|ARO:3004254|vanV_in_vanB_cl	54.2	48	325	114	3.06e-09	53.1
k141_31470_8	SARG|gi|944009777|ref|WP_055601444.1|	34.3	560	596	628	7.22e-74	247
k141_31470_8	SARG|gi|664556405|ref|WP_031071225.1|	33.5	561	596	602	3.05e-73	244
k141_31470_8	SARG|gi|772774655|ref|WP_045322518.1|	33.5	561	596	620	3.21e-73	245
k141_31470_8	SARG|gi|944152509|ref|WP_055644808.1|	33.9	561	596	616	4.11e-73	244
k141_31470_8	SARG|gi|947982677|ref|WP_056642336.1|	34.0	561	596	626	7.07e-73	244
k141_31470_8	SARG|gi|639892676|ref|WP_024755698.1|	34.0	561	596	631	7.85e-73	244
k141_31470_8	SARG|gi|799286378|ref|WP_045936958.1|	32.9	560	596	620	1.69e-72	243
k141_31470_8	SARG|gi|926294973|ref|WP_053631154.1|	32.9	560	596	620	1.69e-72	243
k141_31470_8	SARG|gi|926356413|ref|WP_053687351.1|	32.9	560	596	620	2.35e-72	243
k141_31470_8	SARG|gi|926345639|ref|WP_053677539.1|	32.9	560	596	620	2.35e-72	243
k141_31470_9	SARG|gi|772774655|ref|WP_045322518.1|	31.5	620	606	620	8.62e-81	265
k141_31470_9	SARG|gi|917203192|ref|WP_051809904.1|	31.4	622	606	620	1.21e-80	265
k141_31470_9	SARG|gi|917127754|ref|WP_051734466.1|	31.0	622	606	620	8.97e-80	263
k141_31470_9	SARG|gi|926376632|ref|WP_053705806.1|	31.0	622	606	620	8.97e-80	263
k141_31470_9	SARG|gi|799286378|ref|WP_045936958.1|	31.0	622	606	620	1.25e-79	262
k141_31470_9	SARG|gi|926345639|ref|WP_053677539.1|	31.0	622	606	620	1.75e-79	262
k141_31470_9	SARG|gi|926294973|ref|WP_053631154.1|	30.9	622	606	620	4.77e-79	261
k141_31470_9	SARG|gi|926356413|ref|WP_053687351.1|	30.9	622	606	620	6.66e-79	260
k141_31470_9	SARG|gi|648667297|ref|WP_026359044.1|	30.9	605	606	605	3.66e-77	255
k141_31470_9	SARG|gi|928900436|ref|WP_053931243.1|	30.5	580	606	600	1.24e-76	254
k141_31470_13	SARG|gi|664556405|ref|WP_031071225.1|	38.5	231	498	602	1.35e-24	106
k141_31470_13	SARG|gi|944009777|ref|WP_055601444.1|	36.4	231	498	628	4.65e-22	98.6
k141_31470_13	SARG|gi|446048013|ref|WP_000125868.1|	31.5	222	498	648	1.52e-21	97.1
k141_31470_13	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.0	224	498	664	3.82e-10	61.2
k141_31470_13	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.6	238	498	579	8.14e-10	60.1
k141_31470_13	SARG|DAC81085.1	23.1	169	498	486	4.14e-06	48.1
k141_31470_14	SARG|gi|860594225|ref|WP_048475168.1|	35.7	516	578	620	4.44e-80	263
k141_31470_14	SARG|gi|493394434|ref|WP_006350564.1|	36.5	504	578	602	6.02e-79	259
k141_31470_14	SARG|gi|664556405|ref|WP_031071225.1|	36.0	500	578	602	6.02e-79	259
k141_31470_14	SARG|gi|748767925|ref|WP_040019608.1|	34.9	510	578	623	6.92e-79	259
k141_31470_14	SARG|gi|754608317|ref|WP_041998010.1|	34.0	529	578	612	1.06e-78	259
k141_31470_14	SARG|gi|558888514|ref|WP_023543283.1|	36.4	508	578	615	6.03e-78	257
k141_31470_14	SARG|AF170880.4.gene1.p01	36.2	508	578	615	2.30e-77	255
k141_31470_14	SARG|gi|702897513|ref|WP_033300957.1|	34.9	505	578	601	6.40e-77	254
k141_31470_14	SARG|gi|944009777|ref|WP_055601444.1|	35.2	503	578	628	1.62e-76	253
k141_31470_14	SARG|gi|663330365|ref|WP_030329892.1|	34.9	499	578	607	2.00e-76	253
k141_31470_15	SARG|gi|748767925|ref|WP_040019608.1|	46.0	261	603	623	4.29e-67	229
k141_31470_15	SARG|gi|702897513|ref|WP_033300957.1|	48.1	233	603	601	7.45e-67	228
k141_31470_15	SARG|gi|558888514|ref|WP_023543283.1|	41.4	321	603	615	9.85e-67	228
k141_31470_15	SARG|gi|1033217078|gb|OAR27197.1|	29.5	601	603	601	3.87e-66	226
k141_31470_15	SARG|AF170880.4.gene1.p01	41.1	321	603	615	5.10e-66	226
k141_31470_15	SARG|gi|917203192|ref|WP_051809904.1|	45.6	261	603	620	5.62e-66	226
k141_31470_15	SARG|gi|505420018|ref|WP_015607120.1|	45.8	240	603	603	7.78e-66	225
k141_31470_15	SARG|gi|664352659|ref|WP_030880307.1|	46.2	247	603	601	1.04e-65	224
k141_31470_15	SARG|gi|664100597|ref|WP_030638327.1|	46.2	247	603	601	1.44e-65	224
k141_31470_15	SARG|gi|505389066|ref|WP_015576168.1|	46.2	247	603	601	1.44e-65	224
k141_31470_16	SARG|gi|643601187|ref|WP_025237288.1|	36.3	234	496	648	3.82e-30	123
k141_31470_16	SARG|gi|974628291|ref|WP_059215695.1|	36.3	234	496	648	3.82e-30	123
k141_31470_16	SARG|gi|446110298|ref|WP_000188153.1|	36.3	234	496	648	3.82e-30	123
k141_31470_16	SARG|gi|974633183|ref|WP_059219858.1|	36.3	234	496	648	3.82e-30	123
k141_31470_16	SARG|gi|974684692|ref|WP_059267998.1|	36.3	234	496	648	3.82e-30	123
k141_31470_16	SARG|gi|757799695|ref|WP_043016897.1|	35.3	224	496	648	6.90e-30	122
k141_31470_16	SARG|gi|1045891604|ref|WP_065554100.1|	35.3	224	496	648	6.90e-30	122
k141_31470_16	SARG|gi|507082903|ref|WP_016153652.1|	35.3	224	496	648	6.90e-30	122
k141_31470_16	SARG|gi|835233765|ref|WP_047410073.1|	35.3	224	496	648	6.90e-30	122
k141_31470_16	SARG|gi|754951242|ref|WP_042307417.1|	35.3	224	496	648	6.90e-30	122
k141_31470_20	SARG|gi|921231571|ref|WP_053176464.1|	34.5	478	1195	620	2.35e-63	226
k141_31470_20	SARG|gi|917172177|ref|WP_051778889.1|	34.5	478	1195	620	3.18e-63	226
k141_31470_20	SARG|gi|772774655|ref|WP_045322518.1|	34.9	478	1195	620	5.84e-63	225
k141_31470_20	SARG|gi|917203192|ref|WP_051809904.1|	34.5	478	1195	620	1.96e-62	224
k141_31470_20	SARG|gi|919568551|ref|WP_052871170.1|	34.1	478	1195	620	2.65e-62	223
k141_31470_20	SARG|gi|917229923|ref|WP_051836635.1|	34.5	478	1195	620	3.59e-62	223
k141_31470_20	SARG|gi|799286378|ref|WP_045936958.1|	34.5	478	1195	620	4.86e-62	223
k141_31470_20	SARG|gi|917127754|ref|WP_051734466.1|	34.5	478	1195	620	4.86e-62	223
k141_31470_20	SARG|gi|926294973|ref|WP_053631154.1|	34.5	478	1195	620	4.86e-62	223
k141_31470_20	SARG|gi|926356413|ref|WP_053687351.1|	34.5	478	1195	620	6.58e-62	222
k141_31470_21	CARD|gb|NP_216393.1|ARO:3007662|Rv1877	38.3	509	555	687	1.10e-97	310
k141_31470_21	SARG|BAA07390	35.7	415	555	512	1.32e-75	247
k141_31470_21	SARG|AAD04032	34.1	419	555	563	1.16e-66	225
k141_31470_21	megares|MEG_4381|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	34.1	419	555	563	1.16e-66	225
k141_31470_21	megares|MEG_4380|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	34.1	419	555	563	1.62e-66	224
k141_31470_21	SARG|AAC15775	34.7	409	555	536	4.77e-66	223
k141_31470_21	SARG|CP001581.1.gene725.p01	27.7	393	555	477	3.52e-41	154
k141_31470_21	SARG|gb|AAF40764.1|ARO:3003962|farB	30.5	420	555	508	7.10e-40	150
k141_31470_21	NCBI|AAD54074.1|1|1|farB|farB||1|EFFLUX|EFFLUX|fatty_acid_resistance_MFS_efflux_transporter_permease_subunit_FarB|AMR|efflux	30.6	422	555	507	1.31e-39	150
k141_31470_21	SARG|CP001918.1.gene3442.p01	25.5	396	555	457	2.96e-28	116
k141_31470_32	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	30.7	397	412	429	7.03e-58	194
k141_31470_52	SARG|gb|ALV80601.1|ARO:3003801|bcr-1	34.0	247	426	402	1.27e-31	123
k141_31470_52	SARG|gi|695688999|ref|WP_032634100.1|	32.7	251	426	404	2.84e-24	102
k141_31470_52	NCBI|WP_061345584.1|1|1|cml_Ochro|cml_Ochro|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	31.0	281	426	397	1.66e-23	100
k141_31470_52	SARG|ZP_03044893	34.7	173	426	391	4.47e-22	96.3
k141_31470_52	SARG|gi|693079149|ref|WP_032241520.1|	34.7	173	426	391	6.05e-22	95.9
k141_31470_52	SARG|ZP_03000297	34.1	173	426	391	8.20e-22	95.5
k141_31470_52	SARG|gi|692988893|ref|WP_032177673.1|	34.7	173	426	391	1.11e-21	95.1
k141_31470_52	SARG|gi|693018597|ref|WP_032197292.1|	34.7	173	426	391	1.11e-21	95.1
k141_31470_52	SARG|gi|693161604|ref|WP_032296651.1|	34.7	173	426	391	1.11e-21	95.1
k141_31470_52	SARG|YP_312344	34.7	173	426	391	1.11e-21	95.1
k141_31470_54	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.4	217	238	219	4.85e-44	146
k141_31470_54	CARD|gb|AAG06465.1|ARO:3005063|cprR	37.6	218	238	223	1.50e-40	137
k141_31470_54	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.0	227	238	232	1.66e-38	132
k141_31470_54	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.0	227	238	232	1.66e-38	132
k141_31470_54	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.6	219	238	228	2.11e-38	132
k141_31470_54	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	219	238	219	3.65e-37	129
k141_31470_54	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	219	238	219	5.14e-37	128
k141_31470_54	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	219	238	220	5.28e-37	128
k141_31470_54	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.4	219	238	220	5.28e-37	128
k141_31470_54	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.7	207	238	231	9.92e-37	128
k141_31470_93	SARG|gi|851928815|ref|WP_048221086.1|	37.3	314	1091	648	8.52e-52	192
k141_31470_93	SARG|gi|780033092|ref|WP_045444768.1|	37.3	314	1091	648	8.52e-52	192
k141_31470_93	SARG|gi|493734654|ref|WP_006683876.1|	37.3	316	1091	648	1.65e-50	189
k141_31470_93	SARG|gi|657888313|ref|WP_029592374.1|	36.6	314	1091	648	2.22e-50	188
k141_31470_93	SARG|gi|803568669|ref|WP_046077412.1|	37.1	315	1091	648	4.01e-50	187
k141_31470_93	SARG|gi|446110352|ref|WP_000188207.1|	37.1	315	1091	648	4.01e-50	187
k141_31470_93	SARG|YP_002382193	37.1	315	1091	648	4.01e-50	187
k141_31470_93	SARG|gi|803575554|ref|WP_046081557.1|	37.1	315	1091	648	4.01e-50	187
k141_31470_93	SARG|gi|446110351|ref|WP_000188206.1|	37.1	315	1091	648	4.01e-50	187
k141_31470_93	SARG|gi|749017716|ref|WP_040076354.1|	36.9	312	1091	646	5.24e-50	187
k141_31470_96	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.3	246	338	255	4.74e-41	143
k141_31470_96	SARG|gi|500465078|gb|EOP76697.1|	32.0	203	338	306	3.64e-23	96.7
k141_31470_96	SARG|gi|500448961|gb|EOP61695.1|	32.0	203	338	306	5.01e-23	96.3
k141_31470_96	SARG|gi|500194536|ref|WP_011867743.1|	30.0	203	338	306	1.67e-21	92.0
k141_31470_96	SARG|gi|447195835|ref|WP_001273091.1|	28.8	205	338	306	8.11e-21	90.1
k141_31470_96	SARG|ZP_04081918	28.6	203	338	306	1.53e-20	89.4
k141_31470_96	SARG|gi|447195836|ref|WP_001273092.1|	28.3	205	338	306	2.09e-20	89.0
k141_60954_10	SARG|AE016830.1.gene424.p01	32.0	406	459	505	7.28e-69	226
k141_60954_10	SARG|NC_002951.3237419.p01	32.3	405	459	480	1.06e-63	212
k141_60954_10	SARG|NC_002951.3237948.p01	31.6	389	459	643	5.41e-59	203
k141_60954_10	SARG|ZP_03589930	31.5	425	459	477	2.07e-52	182
k141_60954_10	megares|MEG_3595|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|LMRB_1	31.5	425	459	477	2.07e-52	182
k141_60954_10	SARG|O35018	31.5	425	459	479	2.15e-52	182
k141_60954_10	SARG|gi|1036324608|gb|OAZ67878.1|	31.5	419	459	477	4.01e-52	181
k141_60954_10	SARG|gi|384930133|gb|AFI26811.1|	31.3	425	459	477	5.59e-52	181
k141_60954_10	SARG|gi|1007411670|gb|AMQ72759.1|	31.3	419	459	477	2.10e-51	179
k141_60954_10	SARG|gi|498485855|ref|WP_010787543.1|	30.8	471	459	476	2.87e-51	179
k141_60954_15	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	35.6	216	248	293	6.34e-35	125
k141_60954_15	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.3	211	248	307	2.36e-34	124
k141_60954_15	SARG|gi|445996695|ref|WP_000074550.1|	31.3	211	248	309	1.39e-32	119
k141_60954_15	SARG|gi|500194536|ref|WP_011867743.1|	32.7	211	248	306	2.69e-31	116
k141_60954_20	SARG|gb|APB03219.1|ARO:3003986|TaeA	36.0	656	610	648	1.46e-106	334
k141_60954_20	SARG|gb|NP_388442.1|ARO:3004476|vmlR	29.9	511	610	547	5.39e-59	205
k141_60954_20	SARG|U82085.gene.p01	25.2	531	610	552	1.02e-48	177
k141_60954_20	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	29.6	514	610	485	2.13e-48	175
k141_60954_20	SARG|AY004350.gene.p01	28.7	536	610	492	3.34e-48	174
k141_60954_20	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	540	610	655	4.32e-48	177
k141_60954_20	SARG|gi|488231473|ref|WP_002302681.1|	28.7	536	610	492	1.21e-47	173
k141_60954_20	SARG|gi|488216250|ref|WP_002287458.1|	28.7	536	610	492	1.21e-47	173
k141_60954_20	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.6	549	610	655	1.51e-47	176
k141_60954_20	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	540	610	655	1.51e-47	176
k141_40448_7	SARG|gi|922019548|ref|WP_053299973.1|	34.2	231	376	648	6.45e-30	120
k141_40448_7	SARG|gi|740856590|ref|WP_038641842.1|	34.6	231	376	648	6.45e-30	120
k141_40448_7	SARG|gi|757799695|ref|WP_043016897.1|	34.6	231	376	648	1.18e-29	119
k141_40448_7	SARG|gi|1045891604|ref|WP_065554100.1|	34.6	231	376	648	1.18e-29	119
k141_40448_7	SARG|gi|507082903|ref|WP_016153652.1|	34.6	231	376	648	1.18e-29	119
k141_40448_7	SARG|gi|835233765|ref|WP_047410073.1|	32.8	259	376	648	1.18e-29	119
k141_40448_7	SARG|gi|507086196|ref|WP_016156937.1|	34.6	231	376	648	1.18e-29	119
k141_40448_7	SARG|gi|554685678|ref|WP_023185565.1|	34.2	231	376	648	1.18e-29	119
k141_40448_7	SARG|gi|696411918|ref|WP_032982657.1|	35.5	231	376	647	1.60e-29	119
k141_40448_7	SARG|gi|446048048|ref|WP_000125903.1|	34.2	231	376	648	1.60e-29	119
k141_40448_8	SARG|gb|ADZ12699.1|ARO:3005091|RanA	32.4	210	350	258	1.48e-30	115
k141_40448_8	SARG|gi|895736250|emb|COF64653.1|	31.7	230	350	309	8.21e-29	112
k141_40448_8	SARG|gi|446110087|ref|WP_000187942.1|	31.7	230	350	309	8.21e-29	112
k141_40448_8	SARG|gi|445996714|ref|WP_000074569.1|	31.7	230	350	309	8.21e-29	112
k141_40448_8	SARG|gi|507035724|ref|WP_016107411.1|	31.1	238	350	309	1.58e-28	111
k141_40448_8	SARG|gi|445996698|ref|WP_000074553.1|	31.1	238	350	309	1.58e-28	111
k141_40448_8	SARG|gi|445996723|ref|WP_000074578.1|	31.7	230	350	309	1.58e-28	111
k141_40448_8	SARG|gi|445996719|ref|WP_000074574.1|	31.7	230	350	309	2.18e-28	111
k141_40448_8	SARG|gi|445996697|ref|WP_000074552.1|	31.1	238	350	309	2.18e-28	111
k141_40448_8	SARG|gi|445996722|ref|WP_000074577.1|	31.3	230	350	309	2.18e-28	111
k141_40448_12	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	26.6	203	259	255	3.22e-19	83.2
k141_40448_27	CARD|gb|CAA79966.1|ARO:3003665|NmcR	41.0	61	301	295	8.18e-08	51.6
k141_40448_30	SARG|U09991.1.gene2.p01	30.9	391	420	436	1.52e-29	118
k141_40448_30	NCBI|WP_063844229.1|1|1|cmlV|cmlV|efflux|2|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_MFS_transporter_CmlV|AMR|phenicol	31.0	387	420	412	2.12e-29	117
k141_40448_45	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.6	217	221	228	3.21e-42	141
k141_40448_45	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.2	223	221	232	4.46e-40	136
k141_40448_45	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	224	221	231	4.20e-37	128
k141_40448_45	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	35.5	228	221	239	2.03e-36	127
k141_40448_45	CARD|gb|AAG05188.1|ARO:3005068|ParR	35.8	218	221	235	2.02e-35	124
k141_40448_45	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.4	215	221	219	1.96e-31	113
k141_40448_45	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.0	215	221	219	7.69e-31	112
k141_40448_45	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.0	215	221	220	7.88e-31	112
k141_40448_45	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.0	215	221	220	1.11e-30	111
k141_40448_45	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.6	217	221	220	4.70e-29	107
k141_40448_48	SARG|P42332	47.6	229	233	306	3.40e-69	213
k141_40448_48	SARG|ABB80128	47.6	229	233	306	6.81e-69	213
k141_40448_48	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	47.8	226	233	306	9.63e-69	212
k141_40448_48	SARG|gi|510143239|gb|AGN36970.1|	47.8	226	233	313	1.18e-68	212
k141_40448_48	SARG|AAD21213	47.2	229	233	306	2.73e-68	211
k141_40448_48	SARG|gi|488120365|ref|WP_002191762.1|	49.5	214	233	309	1.19e-67	209
k141_40448_48	SARG|gi|445996709|ref|WP_000074564.1|	46.9	226	233	309	1.69e-67	209
k141_40448_48	SARG|gi|542061059|gb|ERI11611.1|	47.2	229	233	316	2.93e-67	209
k141_40448_48	SARG|gi|447057510|ref|WP_001134766.1|	50.0	214	233	309	3.38e-67	208
k141_40448_48	SARG|gi|500194536|ref|WP_011867743.1|	49.5	214	233	306	4.38e-67	208
k141_22656_2	CARD|gb|NP_216393.1|ARO:3007662|Rv1877	38.7	491	593	687	3.49e-110	344
k141_22656_2	SARG|BAA07390	36.7	493	593	512	7.55e-89	283
k141_22656_2	SARG|ZP_03053667	35.2	495	593	506	3.51e-88	281
k141_22656_2	SARG|YP_001486998	34.9	495	593	530	1.85e-87	280
k141_22656_2	SARG|CAB12101	37.7	419	593	512	6.69e-86	275
k141_22656_2	SARG|AAD04032	38.8	417	593	563	9.13e-86	276
k141_22656_2	megares|MEG_4381|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	38.8	417	593	563	9.13e-86	276
k141_22656_2	SARG|AAC15775	39.4	409	593	536	1.26e-85	275
k141_22656_2	megares|MEG_4380|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	38.8	417	593	563	1.28e-85	276
k141_22656_2	SARG|YP_001419960	33.7	493	593	510	3.45e-85	273
k141_22656_18	SARG|gi|823326845|ref|WP_047080664.1|	34.6	246	311	648	2.53e-31	122
k141_22656_18	SARG|gi|976146774|ref|WP_059305359.1|	34.6	246	311	648	3.45e-31	122
k141_22656_18	SARG|gi|1022664304|ref|WP_063420886.1|	34.6	246	311	648	3.45e-31	122
k141_22656_18	SARG|gi|505807117|ref|WP_015704872.1|	34.6	246	311	648	3.45e-31	122
k141_22656_18	SARG|gi|695797094|ref|WP_032711285.1|	34.6	246	311	648	3.45e-31	122
k141_22656_18	SARG|gi|823299155|ref|WP_047054544.1|	34.6	246	311	648	3.45e-31	122
k141_22656_18	SARG|gi|695793471|ref|WP_032707680.1|	34.6	246	311	648	4.69e-31	121
k141_22656_18	SARG|gi|823302270|ref|WP_047057473.1|	34.6	246	311	648	4.69e-31	121
k141_22656_18	SARG|gi|823309640|ref|WP_047064288.1|	34.6	246	311	648	4.69e-31	121
k141_22656_18	SARG|gi|505180394|ref|WP_015367496.1|	34.6	246	311	648	4.69e-31	121
k141_22656_25	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	30.5	226	287	343	8.57e-19	84.0
k141_22656_27	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	29.6	206	233	293	4.04e-17	77.4
k141_22656_27	SARG|gb|ABX00624.1|ARO:3002881|lmrC	27.0	196	233	550	4.81e-11	60.8
k141_22656_27	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	39.0	77	233	461	1.99e-10	58.9
k141_22656_27	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.7	187	233	574	2.17e-10	58.9
k141_22656_27	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	38.7	75	233	461	4.88e-10	57.8
k141_22656_32	SARG|gi|829908959|ref|WP_047362283.1|	39.8	231	257	646	5.27e-40	145
k141_22656_32	SARG|gi|1006477526|ref|WP_061771940.1|	39.8	231	257	646	5.27e-40	145
k141_22656_32	SARG|gi|896106549|ref|WP_049136608.1|	40.0	235	257	646	7.25e-40	144
k141_22656_32	SARG|gi|654544841|ref|WP_028012549.1|	39.6	235	257	646	9.97e-40	144
k141_22656_32	SARG|gi|556463948|ref|WP_023315739.1|	40.0	235	257	646	9.97e-40	144
k141_22656_32	SARG|gi|779958642|ref|WP_045406003.1|	39.8	236	257	646	9.97e-40	144
k141_22656_32	SARG|gi|498115003|ref|WP_010429159.1|	39.6	235	257	646	9.97e-40	144
k141_22656_32	SARG|gi|1032819400|ref|WP_064325534.1|	38.9	234	257	646	9.97e-40	144
k141_22656_32	SARG|gi|740633514|ref|WP_038419019.1|	41.0	227	257	646	1.37e-39	144
k141_22656_32	SARG|gi|1028090136|ref|WP_063847814.1|	39.6	235	257	646	1.37e-39	144
k141_22656_51	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	45.9	231	237	228	2.61e-62	193
k141_22656_51	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	41.4	237	237	252	5.81e-56	178
k141_22656_51	CARD|gb|AAD51348.1|ARO:3003066|smeR	42.2	223	237	229	3.33e-55	175
k141_22656_51	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.3	225	237	232	1.03e-54	174
k141_22656_51	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.1	224	237	231	1.28e-52	169
k141_22656_51	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	40.5	237	237	239	4.59e-52	167
k141_22656_51	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	41.5	229	237	231	5.14e-52	167
k141_22656_51	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.7	229	237	231	1.03e-51	166
k141_22656_51	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.6	226	237	229	1.37e-51	166
k141_22656_51	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.5	229	237	232	8.45e-51	164
k141_22656_52	CARD|gb|BAB38260.1|ARO:3000830|cpxA	28.6	311	546	457	3.93e-34	133
k141_22656_52	CARD|gb|AEX49906.1|ARO:3003583|basS	32.4	247	546	477	1.12e-27	115
k141_22656_52	CARD|gb|AAC75429.1|ARO:3000833|evgS	27.9	222	546	1197	3.17e-20	94.0
k141_22656_52	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.1	214	546	359	2.01e-19	89.0
k141_22656_52	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	22.9	227	546	364	4.20e-17	82.0
k141_22656_52	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	22.9	227	546	364	4.20e-17	82.0
k141_22656_52	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	24.3	210	546	341	2.98e-11	63.9
k141_6096_2	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	32.1	78	212	210	1.39e-08	52.0
k141_6096_2	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	32.1	78	212	210	1.39e-08	52.0
k141_6096_13	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	38.5	564	553	533	2.72e-91	289
k141_6096_13	SARG|AF353562.gene.p01	35.6	405	553	369	1.84e-49	174
k141_44369_16	SARG|gi|1033217078|gb|OAR27197.1|	33.6	593	625	601	1.05e-75	252
k141_44369_16	SARG|gi|505420018|ref|WP_015607120.1|	33.2	588	625	603	5.81e-75	250
k141_44369_16	SARG|gi|928900436|ref|WP_053931243.1|	35.4	495	625	600	2.86e-74	248
k141_44369_16	SARG|gi|664579989|ref|WP_031094015.1|	35.4	495	625	601	2.93e-74	248
k141_44369_16	SARG|gi|663330365|ref|WP_030329892.1|	34.4	494	625	607	4.66e-74	248
k141_44369_16	SARG|gi|558888514|ref|WP_023543283.1|	33.0	594	625	615	5.54e-74	248
k141_44369_16	SARG|gi|695842130|ref|WP_032755430.1|	33.0	588	625	603	5.95e-74	247
k141_44369_16	SARG|gi|1045390184|ref|WP_065479071.1|	32.9	587	625	605	6.21e-74	247
k141_44369_16	SARG|AF170880.4.gene1.p01	32.8	594	625	615	1.07e-73	247
k141_44369_16	SARG|gi|516795764|ref|WP_018105258.1|	32.5	594	625	601	1.11e-73	246
k141_44369_17	SARG|gi|493394434|ref|WP_006350564.1|	33.8	520	578	602	7.72e-72	240
k141_44369_17	SARG|gi|739906046|ref|WP_037756452.1|	34.2	521	578	620	8.25e-71	238
k141_44369_17	SARG|gi|516574297|ref|WP_017949361.1|	34.0	521	578	620	1.60e-70	237
k141_44369_17	SARG|gi|953808775|ref|WP_058042812.1|	33.6	521	578	608	2.51e-68	231
k141_44369_17	SARG|gi|655413091|ref|WP_028811890.1|	33.9	519	578	603	2.30e-67	228
k141_44369_20	SARG|gi|585358510|ref|WP_024240108.1|	29.9	194	499	648	9.64e-16	79.0
k141_44369_20	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.8	235	499	664	1.24e-14	75.5
k141_44369_20	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	22.3	546	499	487	8.36e-13	69.3
k141_44369_20	SARG|gb|ABX00624.1|ARO:3002881|lmrC	28.1	434	499	550	2.20e-12	68.2
k141_44369_20	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	23.3	417	499	461	2.42e-12	67.8
k141_44369_20	SARG|gb|AAK76136.1|ARO:3000025|patB	24.8	238	499	588	7.13e-12	66.6
k141_44369_20	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	23.5	409	499	461	1.75e-11	65.1
k141_44369_20	SARG|gi|948137056|ref|WP_056795395.1|	28.8	243	499	602	3.89e-11	64.3
k141_44369_20	SARG|gi|517381192|ref|WP_018555350.1|	28.3	251	499	602	6.79e-11	63.5
k141_44369_20	SARG|gb|AVI44920.1|ARO:3004470|poxtA	22.1	375	499	542	3.38e-10	61.2
k141_44369_49	CARD|gb|AEX49906.1|ARO:3003583|basS	29.7	239	563	477	2.24e-19	90.1
k141_44369_50	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.2	230	238	228	1.57e-44	148
k141_44369_50	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	36.8	234	238	239	1.19e-43	146
k141_44369_50	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.6	227	238	232	1.36e-40	138
k141_44369_50	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.2	228	238	231	7.37e-40	136
k141_44369_50	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	33.3	231	238	233	8.15e-32	115
k141_44369_50	CARD|gb|AAG05188.1|ARO:3005068|ParR	29.8	228	238	235	8.56e-32	115
k141_44369_50	CARD|gb|AAG06465.1|ARO:3005063|cprR	30.2	232	238	223	2.70e-30	111
k141_44369_50	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.9	112	238	204	1.80e-06	46.2
k141_44369_61	CARD|gb|WKR28567.1|ARO:3007678|IreK	38.7	586	668	718	4.17e-100	321
k141_44369_62	ResF|penA_1_AF515059_1	28.0	411	925	581	8.49e-23	102
k141_44369_62	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	23.3	434	925	674	4.38e-15	78.6
k141_44369_62	SARG|gb|BAI83385.1|ARO:3003440|mecB	22.9	445	925	674	5.77e-15	78.2
k141_44369_62	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	25.9	355	925	593	1.67e-12	70.1
k141_44369_90	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.5	193	538	361	1.82e-10	61.6
k141_44369_91	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.3	219	237	228	1.21e-46	153
k141_44369_91	CARD|gb|AAD51348.1|ARO:3003066|smeR	35.9	220	237	229	6.94e-43	144
k141_44369_91	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.4	218	237	219	8.09e-39	133
k141_44369_91	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.2	231	237	232	8.12e-39	133
k141_44369_91	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.2	231	237	232	8.12e-39	133
k141_44369_91	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.9	224	237	231	8.23e-35	123
k141_44369_91	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.9	224	237	231	3.23e-34	121
k141_44369_91	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	32.7	220	237	225	2.55e-31	114
k141_44369_91	CARD|gb|AAC73788.1|ARO:3003841|kdpE	32.7	220	237	225	2.55e-31	114
k141_44369_91	CARD|gb|AAG06465.1|ARO:3005063|cprR	32.3	220	237	223	2.46e-26	100
k141_44369_108	CARD|gb|AAC75429.1|ARO:3000833|evgS	27.6	453	909	1197	3.41e-42	166
k141_44369_108	CARD|gb|ADM92606.1|ARO:3000549|adeS	28.3	272	909	361	8.76e-18	85.1
k141_44369_108	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	23.8	273	909	361	1.70e-13	72.0
k141_44369_108	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	23.8	273	909	361	1.70e-13	72.0
k141_44369_108	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	24.3	251	909	361	2.27e-13	71.6
k141_44369_108	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.3	251	909	361	2.27e-13	71.6
k141_44369_108	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	24.4	242	909	364	7.33e-13	70.1
k141_44369_108	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	24.4	242	909	364	7.33e-13	70.1
k141_44369_108	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.7	251	909	352	2.83e-12	68.2
k141_44369_108	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.3	251	909	354	3.82e-12	67.8
k141_44369_112	SARG|gi|511041762|ref|WP_016295754.1|	29.7	283	329	343	3.01e-24	100
k141_44369_112	SARG|gi|696673086|ref|WP_033144146.1|	29.3	283	329	343	1.48e-23	98.2
k141_44369_112	SARG|AAD42184	26.8	365	329	343	2.04e-23	97.8
k141_44369_112	SARG|AF277571.gene.p01	27.0	374	329	343	2.04e-23	97.8
k141_44369_112	SARG|gi|552941803|ref|WP_023042860.1|	26.8	365	329	343	2.04e-23	97.8
k141_44369_112	SARG|ABS72058	26.6	365	329	343	5.29e-23	96.7
k141_44369_112	SARG|gi|447002588|ref|WP_001079844.1|	28.3	367	329	343	1.37e-22	95.5
k141_44369_112	SARG|ACM47287	26.9	360	329	343	1.37e-22	95.5
k141_44369_112	SARG|gi|726981187|ref|WP_033585865.1|	28.3	367	329	340	1.81e-22	95.1
k141_44369_112	SARG|AAD51060	26.6	365	329	343	2.58e-22	94.7
k141_44369_151	SARG|gi|948137056|ref|WP_056795395.1|	30.8	607	733	602	1.78e-65	227
k141_44369_151	SARG|gi|493394434|ref|WP_006350564.1|	31.5	587	733	602	3.40e-65	226
k141_44369_151	SARG|gi|926400371|ref|WP_053728483.1|	32.8	583	733	603	2.42e-64	224
k141_44369_151	SARG|AF170880.4.gene1.p01	33.9	495	733	615	8.05e-64	223
k141_44369_151	SARG|gi|1033217078|gb|OAR27197.1|	30.6	599	733	601	8.47e-64	222
k141_44369_151	SARG|gi|558888514|ref|WP_023543283.1|	33.7	495	733	615	2.12e-63	221
k141_44369_151	SARG|gi|496018010|ref|WP_008742581.1|	31.7	600	733	623	8.93e-63	220
k141_44369_151	SARG|gi|860594225|ref|WP_048475168.1|	30.7	602	733	620	3.05e-62	218
k141_44369_151	SARG|gi|695842130|ref|WP_032755430.1|	29.6	624	733	603	8.02e-62	217
k141_44369_151	SARG|gi|662129758|ref|WP_030081404.1|	30.4	583	733	605	8.33e-62	217
k141_44369_152	SARG|gi|943896259|ref|WP_055534530.1|	44.0	243	724	601	6.46e-50	183
k141_44369_152	SARG|gi|655413091|ref|WP_028811890.1|	42.4	271	724	603	6.66e-50	183
k141_44369_152	SARG|gi|943909899|ref|WP_055545300.1|	42.8	243	724	601	8.82e-50	183
k141_44369_152	SARG|gi|944470764|ref|WP_055701183.1|	41.9	270	724	601	3.06e-49	181
k141_44369_152	SARG|gi|772774655|ref|WP_045322518.1|	40.4	270	724	620	4.03e-49	181
k141_44369_152	SARG|gi|493394434|ref|WP_006350564.1|	41.9	241	724	602	4.24e-49	181
k141_44369_152	SARG|gi|664244930|ref|WP_030776974.1|	43.6	243	724	601	5.70e-49	181
k141_44369_152	SARG|gi|917203192|ref|WP_051809904.1|	40.4	270	724	620	7.49e-49	181
k141_44369_152	SARG|gi|1011969930|ref|WP_062776015.1|	42.8	243	724	601	7.78e-49	180
k141_44369_152	SARG|gi|926376632|ref|WP_053705806.1|	40.4	270	724	620	1.02e-48	180
k141_44369_214	SARG|AUI09862.1	46.3	164	170	287	2.19e-37	129
k141_44369_214	SARG|AJ459418.gene.p01	36.9	160	170	263	3.37e-30	109
k141_44369_214	SARG|gi|490067892|ref|WP_003970071.1|	40.0	155	170	271	3.99e-30	109
k141_44369_214	SARG|gi|970263436|ref|WP_058647620.1|	36.9	160	170	263	6.66e-30	108
k141_44369_214	SARG|gi|486033774|ref|WP_001505252.1|	39.4	155	170	271	2.18e-29	107
k141_44369_214	SARG|gi|916164813|ref|WP_050960181.1|	39.4	155	170	271	3.06e-29	107
k141_44369_214	SARG|gi|920213921|ref|WP_052970363.1|	39.4	155	170	271	4.30e-29	107
k141_44369_214	SARG|gb|AAL59753.1|ARO:3000412|sul2	39.4	155	170	271	6.03e-29	106
k141_44369_214	SARG|gi|1028099083|ref|WP_063855540.1|	39.4	155	170	271	6.03e-29	106
k141_44369_214	SARG|gi|550552396|ref|WP_022631488.1|	39.4	155	170	271	6.03e-29	106
k141_10824_2	SARG|gb|APB03219.1|ARO:3003986|TaeA	38.9	540	560	648	4.51e-115	354
k141_10824_2	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	3.74e-74	247
k141_10824_2	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	1.97e-73	245
k141_10824_2	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	1.97e-73	245
k141_10824_2	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	1.97e-73	245
k141_10824_2	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	1.97e-73	245
k141_10824_2	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	1.97e-73	245
k141_10824_2	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	1.97e-73	245
k141_10824_2	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	1.97e-73	245
k141_10824_2	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	551	560	655	1.97e-73	245
k141_40755_4	SARG|ZP_03589930	33.3	418	626	477	8.02e-55	192
k141_40755_4	megares|MEG_3595|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|LMRB_1	33.3	418	626	477	8.02e-55	192
k141_40755_4	SARG|O35018	33.3	418	626	479	8.37e-55	192
k141_40755_4	SARG|gi|384930133|gb|AFI26811.1|	33.0	418	626	477	1.54e-54	192
k141_40755_4	SARG|gi|498485855|ref|WP_010787543.1|	31.8	425	626	476	2.89e-54	191
k141_40755_4	SARG|gi|504288593|ref|WP_014475695.1|	32.8	418	626	477	1.08e-53	189
k141_40755_4	SARG|gi|695815041|ref|WP_032728901.1|	32.8	418	626	479	1.13e-53	189
k141_40755_4	SARG|gi|1030030526|gb|ANF35167.1|	32.0	425	626	477	7.59e-53	187
k141_40755_4	SARG|gi|503878543|ref|WP_014112537.1|	31.8	418	626	477	1.05e-52	187
k141_40755_4	SARG|gi|1036324608|gb|OAZ67878.1|	31.6	430	626	477	1.05e-52	187
k141_40873_1	SARG|gi|970263436|ref|WP_058647620.1|	39.4	99	278	263	2.17e-09	55.8
k141_40873_1	SARG|AJ459418.gene.p01	39.4	99	278	263	2.17e-09	55.8
k141_40873_1	SARG|gi|691048908|ref|WP_031996364.1|	41.1	95	278	279	7.93e-09	54.3
k141_40873_1	SARG|gi|498321739|ref|WP_010635895.1|	40.9	88	278	279	1.44e-08	53.5
k141_40873_1	SARG|YP_001746870	40.9	88	278	279	1.93e-08	53.1
k141_40873_1	SARG|gi|765470059|ref|WP_044719974.1|	40.9	88	278	279	2.60e-08	52.8
k141_40873_1	SARG|gi|1028098568|ref|WP_063855066.1|	40.9	88	278	275	4.61e-08	52.0
k141_40873_1	megares|MEG_6608|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI_1	40.9	88	278	276	4.63e-08	52.0
k141_40873_1	SARG|gi|459677885|gb|EMH94380.1|	40.9	88	278	276	4.63e-08	52.0
k141_40873_1	SARG|DQ143913.1.gene6.p01	40.9	88	278	276	4.63e-08	52.0
k141_40873_17	SARG|EU408347.1.gene9.p01	27.4	157	863	302	1.35e-06	50.1
k141_40873_17	SARG|gb|WP_081853183.1|ARO:3006885|ELM-1	25.2	151	863	313	5.91e-06	48.1
k141_40873_22	CARD|gb|AAK37618.1|ARO:3005008|TxR	40.3	231	681	318	2.03e-46	166
k141_40873_29	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.2	224	306	352	4.99e-22	93.6
k141_40873_29	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.0	226	306	354	5.10e-22	93.6
k141_40873_29	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.2	224	306	376	6.41e-22	93.6
k141_40873_29	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	27.2	224	306	376	6.41e-22	93.6
k141_40873_29	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.8	224	306	354	3.40e-21	91.3
k141_40873_30	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.7	228	232	232	3.68e-59	185
k141_40873_30	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.7	228	232	232	3.68e-59	185
k141_40873_30	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.7	228	232	228	1.85e-58	183
k141_40873_30	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.9	221	232	219	1.29e-56	178
k141_40873_30	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.9	228	232	231	4.79e-54	172
k141_40873_30	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.6	224	232	231	9.59e-54	171
k141_40873_30	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.1	230	232	231	1.92e-53	171
k141_40873_30	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.9	229	232	231	2.71e-53	170
k141_40873_30	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.9	229	232	231	2.71e-53	170
k141_40873_30	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.5	228	232	231	3.84e-53	170
k141_40873_49	CARD|gb|CYF42523.1|ARO:3004047|kdpD	30.5	893	927	885	5.63e-132	417
k141_40873_49	CARD|gb|AAD51347.1|ARO:3003067|smeS	27.3	220	927	467	8.88e-12	67.4
k141_40873_50	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	50.9	226	236	225	1.56e-75	227
k141_40873_50	CARD|gb|AAC73788.1|ARO:3003841|kdpE	50.9	226	236	225	1.56e-75	227
k141_40873_50	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.1	224	236	229	4.80e-46	152
k141_40873_50	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.0	226	236	232	4.09e-42	142
k141_40873_50	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.0	226	236	232	4.09e-42	142
k141_40873_50	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.9	224	236	231	5.61e-42	141
k141_40873_50	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	34.4	224	236	230	2.16e-41	140
k141_40873_50	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.9	224	236	231	3.14e-41	139
k141_40873_50	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.0	224	236	231	8.81e-41	138
k141_40873_50	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.5	224	236	231	8.81e-41	138
k141_40873_57	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	32.1	190	717	722	1.89e-19	92.0
k141_40873_70	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.7	210	229	204	1.37e-15	71.6
k141_40873_70	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.9	229	229	228	1.72e-12	63.5
k141_40873_70	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.0	125	229	247	2.33e-10	57.8
k141_40873_70	CARD|gb|AAG06465.1|ARO:3005063|cprR	37.2	113	229	223	2.25e-09	54.7
k141_40873_70	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.0	118	229	231	5.24e-08	50.8
k141_40873_70	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.0	120	229	219	4.57e-06	45.1
k141_32267_5	SARG|gi|753534206|pdb|4UWS|B	29.1	220	329	266	2.03e-07	50.4
k141_32267_5	SARG|HM750249.1.gene1.p01	29.5	220	329	266	2.72e-07	50.1
k141_32267_5	SARG|DQ143913.1.gene4.p01	29.5	220	329	266	3.65e-07	49.7
k141_32267_5	SARG|FR748153.1.gene2.p01	29.1	220	329	266	3.65e-07	49.7
k141_32267_5	SARG|gb|AGS82586.1|ARO:3002309|VIM-39	29.1	220	329	266	3.65e-07	49.7
k141_32267_5	SARG|gb|WP_063865197.1|ARO:3005495|VIM-47	31.4	175	329	266	3.65e-07	49.7
k141_32267_5	SARG|DQ365886.1.gene1.p01	31.4	175	329	266	3.65e-07	49.7
k141_32267_5	NCBI|WP_394294925.1|1|1|blaVIM-90|blaVIM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B1_metallo-beta-lactamase_VIM-90|AMR|beta-lactam	27.9	219	329	266	6.56e-07	48.9
k141_32267_5	SARG|gi|983425423|ref|WP_060589395.1|	29.1	220	329	266	6.56e-07	48.9
k141_32267_5	SARG|JF900599.1.gene1.p01	30.9	175	329	266	1.18e-06	48.1
k141_32267_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	227	232	231	6.26e-43	144
k141_32267_7	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.0	227	232	232	1.81e-42	142
k141_32267_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.3	220	232	228	2.55e-41	139
k141_32267_7	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	36.1	238	232	252	3.27e-38	132
k141_32267_7	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	33.5	233	232	239	4.66e-38	131
k141_32267_7	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.9	222	232	229	2.00e-37	129
k141_32267_7	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.6	224	232	219	6.29e-33	117
k141_32267_7	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.6	224	232	219	8.86e-33	117
k141_32267_7	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.6	224	232	220	9.08e-33	117
k141_32267_7	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.6	224	232	220	1.28e-32	117
k141_32267_9	SARG|gi|639225329|ref|WP_024561799.1|	38.6	249	258	648	2.95e-47	165
k141_32267_9	SARG|gi|639218559|ref|WP_024556062.1|	38.6	249	258	648	2.95e-47	165
k141_32267_9	SARG|gi|896325272|ref|WP_049294291.1|	37.5	269	258	648	7.83e-47	164
k141_32267_9	SARG|gb|AAV85982.1|ARO:3000535|macB	37.7	231	258	644	1.44e-46	163
k141_32267_9	SARG|gi|657888313|ref|WP_029592374.1|	37.2	266	258	648	2.07e-46	162
k141_32267_9	SARG|gi|639216333|ref|WP_024554080.1|	37.5	269	258	648	2.07e-46	162
k141_32267_9	SARG|gi|751930065|ref|WP_041144773.1|	37.6	250	258	648	2.86e-46	162
k141_32267_9	SARG|gi|1033064422|ref|WP_064375412.1|	37.2	247	258	648	5.48e-46	161
k141_32267_9	SARG|gi|823326845|ref|WP_047080664.1|	36.0	247	258	648	7.57e-46	161
k141_32267_9	SARG|gi|823302270|ref|WP_047057473.1|	36.0	247	258	648	1.45e-45	160
k141_32267_14	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	37.7	69	312	291	1.20e-06	48.1
k141_61398_2	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	29.0	610	725	633	8.35e-68	234
k141_6337_4	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	27.9	420	437	429	2.35e-52	180
k141_6337_29	SARG|gi|896106549|ref|WP_049136608.1|	36.5	170	189	646	1.55e-25	101
k141_6337_29	SARG|gi|654544841|ref|WP_028012549.1|	36.5	170	189	646	2.11e-25	101
k141_6337_29	SARG|gi|829942568|ref|WP_047368199.1|	36.5	170	189	646	2.11e-25	101
k141_6337_29	SARG|gb|AAV85982.1|ARO:3000535|macB	31.9	185	189	644	6.38e-22	91.3
k141_53430_8	CARD|gb|ABD30512.1|ARO:3000839|arlS	27.8	306	469	451	2.98e-26	109
k141_53430_8	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	28.6	248	469	392	8.85e-22	95.9
k141_53430_9	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.3	227	231	228	9.84e-50	161
k141_53430_9	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.1	183	231	219	6.14e-43	143
k141_53430_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.0	227	231	231	2.68e-41	139
k141_53430_9	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.9	227	231	232	3.89e-41	139
k141_53430_9	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.2	232	231	231	7.54e-41	138
k141_53430_9	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.9	231	231	231	2.98e-40	137
k141_53430_9	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.9	231	231	231	4.21e-40	136
k141_53430_9	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.0	228	231	219	4.29e-40	136
k141_53430_9	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.0	228	231	220	4.41e-40	136
k141_53430_9	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.9	231	231	231	5.94e-40	136
k141_53430_10	SARG|gi|505420018|ref|WP_015607120.1|	33.6	238	290	603	5.35e-30	117
k141_53430_10	SARG|gi|695842130|ref|WP_032755430.1|	33.2	238	290	603	8.66e-29	114
k141_53430_10	SARG|gi|944009777|ref|WP_055601444.1|	33.6	220	290	628	6.77e-27	108
k141_53430_10	SARG|gi|695865802|ref|WP_032778631.1|	32.4	238	290	605	8.77e-27	108
k141_53430_10	SARG|gi|664458452|ref|WP_030980047.1|	33.6	220	290	601	1.60e-26	107
k141_53430_10	SARG|gi|664556405|ref|WP_031071225.1|	32.1	240	290	602	2.18e-26	107
k141_53430_10	SARG|gi|917229923|ref|WP_051836635.1|	32.6	233	290	620	2.26e-26	107
k141_53430_10	SARG|gi|748767925|ref|WP_040019608.1|	32.8	238	290	623	2.28e-26	107
k141_53430_10	SARG|gi|493394434|ref|WP_006350564.1|	32.3	235	290	602	2.97e-26	107
k141_53430_10	SARG|gi|944152509|ref|WP_055644808.1|	33.0	233	290	616	4.14e-26	106
k141_53430_21	SARG|gi|749574782|ref|WP_040203616.1|	36.6	262	321	323	7.48e-36	130
k141_53430_21	SARG|gi|985522333|ref|WP_060811962.1|	36.8	296	321	323	1.46e-35	130
k141_53430_21	SARG|YP_002333394	36.9	290	321	323	3.97e-35	129
k141_53430_21	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	36.9	290	321	323	3.97e-35	129
k141_53430_21	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	34.4	259	321	343	4.25e-35	129
k141_53430_21	SARG|NP_878015	35.4	288	321	322	5.42e-35	128
k141_53430_21	SARG|Q47748	36.5	296	321	323	7.72e-35	128
k141_53430_21	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	35.7	241	321	348	9.09e-35	128
k141_53430_21	SARG|gb|AAB05626.1|ARO:3002943|vanHB	36.5	296	321	323	1.08e-34	127
k141_53430_21	SARG|AF310956.2.gene5.p01	36.6	290	321	323	1.50e-34	127
k141_53430_28	SARG|gi|488053456|ref|WP_002124853.1|	39.7	209	238	309	4.66e-40	139
k141_53430_28	SARG|gi|447057509|ref|WP_001134765.1|	40.2	209	238	309	4.66e-40	139
k141_53430_28	SARG|gi|488067981|ref|WP_002139378.1|	39.7	209	238	309	9.21e-40	138
k141_53430_28	SARG|gi|487936534|ref|WP_002010000.1|	39.7	209	238	309	9.21e-40	138
k141_53430_28	SARG|gi|447057510|ref|WP_001134766.1|	39.7	209	238	309	9.21e-40	138
k141_53430_28	SARG|gi|488068784|ref|WP_002140181.1|	39.2	209	238	309	1.82e-39	137
k141_53430_28	SARG|gi|507055561|ref|WP_016126482.1|	39.7	209	238	309	2.56e-39	137
k141_53430_28	SARG|gi|447195835|ref|WP_001273091.1|	38.5	213	238	306	3.36e-39	136
k141_53430_28	SARG|gi|445996719|ref|WP_000074574.1|	39.7	209	238	309	3.59e-39	136
k141_53430_28	SARG|gi|507023808|ref|WP_016095885.1|	39.2	209	238	309	3.59e-39	136
k141_53430_34	SARG|gi|742378414|ref|WP_038857601.1|	43.1	248	248	647	8.40e-54	182
k141_53430_34	SARG|YP_001438541	42.7	248	248	647	1.62e-53	181
k141_53430_34	SARG|gi|938461734|ref|WP_054625806.1|	42.7	248	248	647	1.62e-53	181
k141_53430_34	SARG|gi|1020141879|ref|WP_063264839.1|	42.7	248	248	647	1.62e-53	181
k141_53430_34	SARG|gi|490522515|ref|WP_004387938.1|	42.7	248	248	647	1.62e-53	181
k141_53430_34	SARG|gi|506220920|ref|WP_015740695.1|	42.7	248	248	647	2.26e-53	181
k141_53430_34	SARG|gi|829908959|ref|WP_047362283.1|	43.4	249	248	646	3.10e-53	181
k141_53430_34	SARG|gi|985815823|ref|WP_060876116.1|	42.7	246	248	646	3.10e-53	181
k141_53430_34	SARG|YP_002239469	42.7	246	248	646	3.10e-53	181
k141_53430_34	SARG|gi|1006477526|ref|WP_061771940.1|	43.4	249	248	646	3.10e-53	181
k141_53430_48	SARG|BBJ25230.1	34.4	93	348	263	1.71e-06	47.8
k141_53430_58	SARG|AE016830.1.gene424.p01	36.7	417	486	505	7.76e-91	285
k141_53430_58	SARG|NC_002951.3237419.p01	34.3	452	486	480	8.79e-82	260
k141_53430_58	SARG|NC_002951.3238155.p01	33.3	400	486	465	3.46e-76	245
k141_53430_58	SARG|NC_009641.5331418.p01	33.7	392	486	452	2.87e-74	240
k141_53430_58	SARG|NC_002951.3237948.p01	31.3	415	486	643	5.07e-69	231
k141_53430_58	SARG|gi|631799622|gb|AHZ14287.1|	32.7	419	486	477	7.55e-63	211
k141_53430_58	SARG|gi|1007411670|gb|AMQ72759.1|	32.7	419	486	477	2.07e-62	209
k141_53430_58	SARG|gi|393806119|gb|EJD67473.1|	32.7	419	486	477	2.89e-62	209
k141_53430_58	SARG|YP_001419928	32.2	419	486	477	2.89e-62	209
k141_53430_58	SARG|gi|371566923|emb|CCF03773.1|	32.2	419	486	477	7.90e-62	208
k141_53430_93	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	27.9	251	330	314	7.62e-25	101
k141_53430_93	SARG|KF478993.1.gene2.p01	30.5	259	330	350	1.29e-24	101
k141_53430_93	SARG|gi|737310392|ref|WP_035293250.1|	29.2	257	330	323	5.24e-22	93.6
k141_53430_93	SARG|DQ018711.1.gene4.p01	29.2	257	330	322	1.34e-21	92.4
k141_53430_93	SARG|gi|749574782|ref|WP_040203616.1|	30.4	253	330	323	1.86e-21	92.0
k141_53430_93	SARG|AAY52004	28.8	260	330	322	3.46e-21	91.3
k141_53430_93	SARG|gi|738848198|ref|WP_036737307.1|	29.6	257	330	323	4.81e-21	90.9
k141_53430_93	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	29.3	263	330	351	4.89e-21	91.3
k141_53430_93	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	28.7	258	330	348	1.21e-20	90.1
k141_53430_93	SARG|AF310956.2.gene5.p01	28.2	255	330	323	1.70e-20	89.4
k141_53430_126	NCBI|WP_070509550.1|1|1|mef(H)|mef(H)|efflux|2|ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(H)|AMR|macrolide	37.8	405	425	412	1.79e-88	273
k141_53430_126	SARG|gb|QQM99829.1|ARO:3007047|mefH	33.7	98	425	109	4.58e-13	64.3
k141_53430_127	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	39.3	56	226	210	5.64e-06	44.7
k141_53430_127	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	39.3	56	226	210	5.64e-06	44.7
k141_2699_1	SARG|gi|1033064422|ref|WP_064375412.1|	41.4	58	55	648	3.00e-09	49.3
k141_2699_1	SARG|gi|974588181|ref|WP_059178476.1|	41.4	58	55	646	7.69e-09	48.1
k141_2699_1	SARG|YP_001176128	41.4	58	55	646	7.69e-09	48.1
k141_2699_1	SARG|gi|823326845|ref|WP_047080664.1|	39.7	58	55	648	7.69e-09	48.1
k141_2699_1	SARG|gi|823291602|ref|WP_047047573.1|	39.7	58	55	648	7.69e-09	48.1
k141_2699_1	SARG|gi|823302270|ref|WP_047057473.1|	39.7	58	55	648	7.69e-09	48.1
k141_2699_1	SARG|gi|976146774|ref|WP_059305359.1|	39.7	58	55	648	7.69e-09	48.1
k141_2699_1	SARG|gi|1022664304|ref|WP_063420886.1|	39.7	58	55	648	7.69e-09	48.1
k141_2699_1	SARG|gi|823309640|ref|WP_047064288.1|	39.7	58	55	648	7.69e-09	48.1
k141_2699_1	SARG|gi|505807117|ref|WP_015704872.1|	39.7	58	55	648	7.69e-09	48.1
k141_2699_4	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	35.1	205	259	307	1.64e-34	125
k141_2699_4	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	24.9	197	259	550	1.47e-08	53.9
k141_2699_12	SARG|gi|657888313|ref|WP_029592374.1|	31.8	217	261	648	5.38e-26	105
k141_2699_12	SARG|gi|639216333|ref|WP_024554080.1|	32.7	217	261	648	9.92e-26	104
k141_2699_12	SARG|gi|639225329|ref|WP_024561799.1|	32.1	212	261	648	3.37e-25	103
k141_2699_12	SARG|gi|639218559|ref|WP_024556062.1|	32.1	212	261	648	3.37e-25	103
k141_2699_12	SARG|gi|896325272|ref|WP_049294291.1|	33.2	205	261	648	8.42e-25	102
k141_2699_12	SARG|gi|495004199|ref|WP_007730213.1|	32.6	221	261	647	2.40e-23	97.8
k141_2699_12	SARG|gi|696411918|ref|WP_032982657.1|	32.7	217	261	647	5.98e-23	96.7
k141_2699_12	SARG|gi|742409107|ref|WP_038888226.1|	32.3	220	261	647	1.10e-22	95.9
k141_2699_12	SARG|gi|696402390|ref|WP_032974230.1|	32.7	217	261	647	1.10e-22	95.9
k141_2699_12	SARG|gi|696423952|ref|WP_032993748.1|	32.7	217	261	647	1.10e-22	95.9
k141_2699_26	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	36.8	435	430	444	6.01e-68	221
k141_6486_21	SARG|AE016830.1.gene424.p01	45.0	420	498	505	4.36e-128	381
k141_6486_21	SARG|NC_002951.3237948.p01	42.0	414	498	643	9.30e-107	330
k141_6486_21	SARG|NC_002951.3237419.p01	38.4	417	498	480	3.39e-96	298
k141_6486_21	SARG|NC_002951.3238155.p01	36.5	397	498	465	6.18e-89	279
k141_6486_21	SARG|gi|384930133|gb|AFI26811.1|	38.8	405	498	477	2.42e-88	278
k141_6486_21	SARG|ZP_03589930	38.5	405	498	477	2.42e-88	278
k141_6486_21	megares|MEG_3595|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|LMRB_1	38.5	405	498	477	2.42e-88	278
k141_6486_21	SARG|O35018	38.5	405	498	479	2.56e-88	278
k141_6486_21	SARG|gi|498485855|ref|WP_010787543.1|	37.0	405	498	476	5.11e-87	274
k141_6486_21	SARG|gi|503878543|ref|WP_014112537.1|	37.3	405	498	477	1.04e-86	273
k141_6623_30	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.5	305	312	343	1.31e-51	172
k141_6623_30	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	32.6	313	312	325	7.41e-45	154
k141_6623_30	SARG|gb|AAA26793|ARO:3003748|oleC	32.3	313	312	325	2.05e-44	153
k141_6623_30	SARG|gb|AAR96051.1|ARO:3002894|otrC	29.2	318	312	351	2.16e-31	119
k141_6623_30	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	28.9	318	312	351	1.55e-30	117
k141_6623_30	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.9	214	312	258	7.41e-26	102
k141_6623_30	SARG|gb|AAK76137.1|ARO:3000024|patA	28.0	211	312	564	2.02e-16	78.6
k141_6623_30	SARG|gb|APB03219.1|ARO:3003986|TaeA	24.5	253	312	648	6.50e-10	58.9
k141_6623_32	CARD|gb|BAB36671.1|ARO:3000832|evgA	23.2	198	214	204	1.96e-15	70.9
k141_6623_32	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	37.3	102	214	252	5.51e-11	59.3
k141_6623_32	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.3	102	214	228	2.60e-09	54.3
k141_41113_7	SARG|AE016830.1.gene424.p01	47.9	411	658	505	1.10e-117	360
k141_41113_7	SARG|NC_002951.3237419.p01	40.9	474	658	480	1.06e-106	330
k141_41113_7	SARG|NC_002951.3237948.p01	43.4	417	658	643	2.91e-99	316
k141_41113_7	SARG|NC_002951.3238155.p01	40.5	420	658	465	5.26e-94	297
k141_41113_7	SARG|NC_009641.5331418.p01	40.4	406	658	452	2.48e-90	287
k141_41113_7	SARG|gi|384930133|gb|AFI26811.1|	35.7	454	658	477	7.39e-78	255
k141_41113_7	SARG|ZP_03589930	37.2	406	658	477	7.39e-78	255
k141_41113_7	megares|MEG_3595|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|LMRB_1	37.2	406	658	477	7.39e-78	255
k141_41113_7	SARG|O35018	37.2	406	658	479	7.79e-78	255
k141_41113_7	SARG|gi|631799622|gb|AHZ14287.1|	34.3	461	658	477	2.11e-76	251
k141_41113_10	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	25.9	220	280	568	3.32e-09	56.2
k141_41113_10	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	26.8	205	280	528	1.38e-08	54.3
k141_41113_10	SARG|gb|ABX00624.1|ARO:3002881|lmrC	27.3	194	280	550	5.98e-08	52.4
k141_41113_10	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	30.4	138	280	461	3.16e-06	47.0
k141_41113_11	SARG|gb|AAV85982.1|ARO:3000535|macB	32.7	223	283	644	2.03e-28	113
k141_41113_11	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.3	216	283	343	8.05e-23	95.1
k141_41113_11	SARG|P42332	29.2	236	283	306	8.49e-21	89.0
k141_41113_11	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	29.2	236	283	306	8.49e-21	89.0
k141_41113_11	SARG|gi|510143239|gb|AGN36970.1|	29.2	236	283	313	9.31e-21	89.0
k141_41113_11	SARG|gi|671541568|ref|WP_031525212.1|	28.4	225	283	648	2.26e-20	89.7
k141_41113_11	SARG|ABB80128	29.6	216	283	306	4.21e-20	87.0
k141_41113_11	SARG|gi|542061059|gb|ERI11611.1|	30.8	214	283	316	1.24e-19	85.9
k141_41113_11	SARG|gi|500448961|gb|EOP61695.1|	29.6	213	283	306	1.40e-18	82.8
k141_41113_11	SARG|gi|500465078|gb|EOP76697.1|	29.3	215	283	306	9.31e-18	80.5
k141_2928_46	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.5	240	337	307	1.75e-16	77.8
k141_2928_46	SARG|gb|WP_104671188.1|ARO:3003948|efrA	26.6	248	337	575	4.36e-12	65.9
k141_2928_46	SARG|gb|AAK76137.1|ARO:3000024|patA	21.8	234	337	564	7.57e-09	55.8
k141_2928_46	SARG|gi|171851258|emb|CAQ04234.1|	45.8	59	337	483	1.56e-06	48.5
k141_2928_46	SARG|gi|736993687|ref|WP_034989673.1|	44.1	59	337	513	3.76e-06	47.4
k141_2928_46	SARG|AF024666.2.gene6.p01	44.1	59	337	513	3.76e-06	47.4
k141_2928_46	SARG|AAA50325	27.4	190	337	569	5.21e-06	47.0
k141_2928_48	SARG|CAA37477	30.2	361	604	663	1.84e-33	134
k141_2928_48	SARG|NP_348076	30.8	367	604	652	3.13e-33	134
k141_2928_48	SARG|ZP_02952732	48.6	144	604	652	7.87e-32	129
k141_2928_48	SARG|L20800.gene.p01	48.6	144	604	652	7.87e-32	129
k141_2928_48	SARG|ZP_02632674	48.6	144	604	660	8.16e-32	129
k141_2928_48	SARG|YP_002850805	46.5	144	604	652	3.38e-31	127
k141_2928_48	SARG|AAV80410	27.1	350	604	651	1.93e-30	125
k141_2928_48	SARG|L42544.gene.p01	27.4	350	604	651	3.44e-30	124
k141_2928_48	SARG|AJ514254.gene.p01	33.5	272	604	640	1.05e-29	123
k141_2928_48	SARG|AAZ79478	36.8	239	604	657	1.51e-28	119
k141_2928_54	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	43.1	691	649	703	2.85e-173	509
k141_2928_67	SARG|CP001581.1.gene3143.p01	35.1	333	354	344	8.97e-59	192
k141_2928_67	SARG|gb|CAL84423.1|ARO:3004146|cfrC	34.8	333	354	344	2.74e-57	188
k141_2928_67	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	34.3	338	354	379	1.55e-54	182
k141_2928_67	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	34.3	338	354	416	2.66e-54	182
k141_2928_67	SARG|gb|BAH45481.1|ARO:3002815|clbB	31.8	330	354	343	1.94e-48	165
k141_2928_68	SARG|gi|511041762|ref|WP_016295754.1|	39.1	256	308	343	3.18e-47	160
k141_2928_68	SARG|gi|696673086|ref|WP_033144146.1|	38.7	256	308	343	8.79e-47	159
k141_2928_68	SARG|AF277571.gene.p01	38.3	256	308	343	1.73e-46	159
k141_2928_68	SARG|gi|1028100561|ref|WP_063856696.1|	39.3	247	308	349	7.74e-46	157
k141_2928_68	SARG|BAE96117	37.9	256	308	343	3.67e-45	155
k141_2928_68	NCBI|WP_015943583.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	38.4	255	308	341	9.67e-45	154
k141_2928_68	megares|MEG_7409|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_2	39.0	254	308	293	1.17e-44	152
k141_2928_68	SARG|AAD42184	36.7	256	308	343	1.42e-44	154
k141_2928_68	SARG|gi|752682279|ref|WP_041330231.1|	38.5	247	308	349	1.63e-44	154
k141_2928_68	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_5	38.6	254	308	281	1.70e-44	152
k141_11472_5	SARG|gb|ABA71733.1|ARO:3002972|vanTG	29.0	389	468	712	6.14e-44	163
k141_11472_5	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	29.5	380	468	712	3.48e-42	158
k141_11472_5	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	31.4	322	468	700	3.18e-36	140
k141_11472_5	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	31.7	322	468	700	7.90e-36	139
k141_11472_5	SARG|AAY67970	30.0	317	468	698	8.78e-35	136
k141_11472_5	SARG|AF162694.1.gene4.p01	30.0	317	468	698	1.60e-34	135
k141_11472_5	SARG|gi|657686198|ref|WP_029487032.1|	30.0	317	468	698	1.60e-34	135
k141_11472_5	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.4	322	468	700	9.81e-34	133
k141_11472_5	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.1	322	468	706	6.03e-33	131
k141_11472_5	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	26.7	389	468	711	1.85e-29	120
k141_11472_18	SARG|YP_001419960	28.1	402	587	510	9.05e-41	154
k141_11472_18	SARG|AAC15775	31.3	483	587	536	1.38e-31	127
k141_11472_18	SARG|AAD04032	31.3	483	587	563	1.73e-31	127
k141_11472_18	megares|MEG_4380|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	31.3	483	587	563	1.73e-31	127
k141_11472_18	megares|MEG_4381|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	31.3	483	587	563	1.73e-31	127
k141_11472_18	SARG|gb|BAB43261.1|ARO:3007013|sdrM	29.1	302	587	447	9.91e-29	118
k141_11472_18	SARG|gi|917770481|ref|WP_052284485.1|	28.3	332	587	512	1.41e-28	118
k141_11472_18	SARG|gi|493870778|ref|WP_006817302.1|	29.2	332	587	512	2.55e-28	117
k141_11472_18	NCBI|AMD83542.1|1|1|aadT|aadT||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_AadT|AMR|efflux	27.2	367	587	504	5.80e-28	116
k141_11472_18	SARG|gi|754956999|ref|WP_042313106.1|	27.7	329	587	512	8.74e-27	113
k141_11472_33	NCBI|WP_115421099.1|1|1|cml_Ensi|cml_Ensi|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	31.1	161	403	400	4.91e-08	53.5
k141_11472_33	megares|MEG_8021|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	31.1	161	403	400	4.91e-08	53.5
k141_11472_33	SARG|gi|1039004533|ref|WP_064760451.1|	36.3	102	403	511	7.38e-07	50.1
k141_11472_33	NCBI|WP_112021705.1|1|1|qepA9|qepA|efflux|2|quinolone|quinolone|quinolone_efflux_MFS_transporter_QepA9|AMR|quinolone	36.3	102	403	511	7.38e-07	50.1
k141_11472_33	NCBI|WP_113334341.1|1|1|qepA10|qepA|efflux|2|||quinolone_efflux_MFS_transporter_QepA10|AMR|quinolone	36.3	102	403	506	1.70e-06	48.9
k141_11472_33	SARG|gi|1028098233|ref|WP_063854778.1|	36.3	102	403	511	1.71e-06	48.9
k141_11472_33	SARG|gb|AEZ36150.1|ARO:3000448|qepA	36.3	102	403	511	1.71e-06	48.9
k141_11472_33	SARG|NC_010558.1.6275948.p01	36.3	102	403	511	1.71e-06	48.9
k141_11472_33	NCBI|WP_096941464.1|1|1|qepA6|qepA|efflux|2|||quinolone_efflux_MFS_transporter_QepA6|AMR|quinolone	35.3	102	403	511	2.27e-06	48.5
k141_11472_33	NCBI|WP_109638756.1|1|1|qepA8|qepA|efflux|2|quinolone|quinolone|quinolone_efflux_MFS_transporter_QepA8|AMR|quinolone	35.3	102	403	513	2.27e-06	48.5
k141_23604_3	CARD|gb|ADM92605.1|ARO:3000553|adeR	28.5	130	749	247	4.34e-07	50.8
k141_15233_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.0	230	676	255	1.22e-23	99.8
k141_15233_6	SARG|gi|974633183|ref|WP_059219858.1|	32.5	234	676	648	2.44e-23	103
k141_15233_6	SARG|gi|974684692|ref|WP_059267998.1|	32.5	234	676	648	2.44e-23	103
k141_15233_6	SARG|gi|643601187|ref|WP_025237288.1|	32.5	234	676	648	3.24e-23	103
k141_15233_6	SARG|gi|974628291|ref|WP_059215695.1|	32.5	234	676	648	3.24e-23	103
k141_15233_6	SARG|gi|446110298|ref|WP_000188153.1|	32.5	234	676	648	3.24e-23	103
k141_15233_6	SARG|gi|693054987|ref|WP_032223114.1|	33.3	231	676	648	4.29e-23	103
k141_15233_6	SARG|gi|974672242|ref|WP_059256507.1|	32.5	234	676	648	5.69e-23	102
k141_15233_6	SARG|gi|974641719|ref|WP_059227752.1|	32.5	234	676	648	5.69e-23	102
k141_15233_6	SARG|gi|446110299|ref|WP_000188154.1|	32.5	234	676	648	5.69e-23	102
k141_15233_7	SARG|gi|664244930|ref|WP_030776974.1|	30.2	252	287	601	4.75e-19	85.9
k141_15233_7	SARG|gb|AAK76137.1|ARO:3000024|patA	26.8	224	287	564	1.25e-13	69.7
k141_15233_7	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.5	253	287	574	1.34e-12	66.6
k141_11612_7	SARG|NP_348076	28.8	139	921	652	3.92e-09	59.3
k141_11612_7	SARG|ZP_02952732	24.1	187	921	652	2.67e-08	56.6
k141_11612_7	SARG|L20800.gene.p01	24.1	187	921	652	2.67e-08	56.6
k141_11612_7	SARG|ZP_02632674	24.1	187	921	660	2.69e-08	56.6
k141_54038_11	SARG|gi|654544841|ref|WP_028012549.1|	29.8	121	964	646	4.36e-07	52.8
k141_54038_11	SARG|gi|896106549|ref|WP_049136608.1|	29.8	121	964	646	4.36e-07	52.8
k141_54038_11	SARG|gi|829942568|ref|WP_047368199.1|	29.8	121	964	646	4.36e-07	52.8
k141_45137_33	SARG|gb|ABX00624.1|ARO:3002881|lmrC	31.3	201	491	550	8.79e-08	53.5
k141_45137_33	megares|MEG_7256|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|TLRC_1	30.3	185	491	540	1.41e-06	49.7
k141_45137_37	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.0	540	492	655	1.12e-13	72.4
k141_45137_37	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.0	540	492	655	1.12e-13	72.4
k141_45137_37	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.2	537	492	655	1.96e-13	71.6
k141_45137_37	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.5	540	492	655	2.59e-13	71.2
k141_45137_37	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.5	540	492	655	4.54e-13	70.5
k141_45137_37	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.5	540	492	655	4.54e-13	70.5
k141_45137_37	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.5	540	492	655	4.54e-13	70.5
k141_45137_37	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.5	540	492	655	6.01e-13	70.1
k141_45137_37	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.5	540	492	655	6.01e-13	70.1
k141_45137_37	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.9	540	492	655	7.95e-13	69.7
k141_45137_38	SARG|gi|926376632|ref|WP_053705806.1|	33.4	605	620	620	2.94e-83	272
k141_45137_38	SARG|gi|799286378|ref|WP_045936958.1|	33.4	605	620	620	5.75e-83	271
k141_45137_38	SARG|gi|926345639|ref|WP_053677539.1|	33.4	605	620	620	8.04e-83	271
k141_45137_38	SARG|gi|917203192|ref|WP_051809904.1|	33.2	605	620	620	1.12e-82	271
k141_45137_38	SARG|gi|926294973|ref|WP_053631154.1|	33.2	605	620	620	2.20e-82	270
k141_45137_38	SARG|gi|926356413|ref|WP_053687351.1|	33.2	605	620	620	3.07e-82	270
k141_45137_38	SARG|gi|917127754|ref|WP_051734466.1|	33.2	605	620	620	4.29e-82	269
k141_45137_38	SARG|gi|860594225|ref|WP_048475168.1|	33.5	591	620	620	8.38e-82	268
k141_45137_38	SARG|gi|772774655|ref|WP_045322518.1|	32.9	605	620	620	1.64e-81	268
k141_45137_38	SARG|gi|917166849|ref|WP_051773561.1|	34.9	516	620	620	6.24e-81	266
k141_45137_39	SARG|gi|1033217078|gb|OAR27197.1|	32.7	544	582	601	4.38e-71	238
k141_45137_39	SARG|gi|860594225|ref|WP_048475168.1|	32.3	538	582	620	1.76e-70	237
k141_45137_39	SARG|gi|926400371|ref|WP_053728483.1|	32.8	540	582	603	2.40e-70	236
k141_45137_39	SARG|gi|493394434|ref|WP_006350564.1|	30.3	584	582	602	3.28e-70	236
k141_45137_39	SARG|gi|944009777|ref|WP_055601444.1|	32.1	595	582	628	2.92e-69	234
k141_45137_39	SARG|gi|917166849|ref|WP_051773561.1|	30.6	582	582	620	1.81e-68	232
k141_45137_39	SARG|gi|772774655|ref|WP_045322518.1|	31.2	542	582	620	1.81e-68	232
k141_45137_39	SARG|gi|748767925|ref|WP_040019608.1|	43.5	269	582	623	1.92e-68	232
k141_45137_39	SARG|gi|917155568|ref|WP_051762280.1|	30.6	582	582	620	2.52e-68	231
k141_45137_39	SARG|gi|926376632|ref|WP_053705806.1|	30.8	542	582	620	3.50e-68	231
k141_11912_13	SARG|gb|AAC75271.1|ARO:3003952|yojI	30.1	216	320	547	4.44e-14	71.6
k141_11912_13	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	26.4	212	320	505	2.44e-13	69.3
k141_11912_13	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	26.9	212	320	504	7.84e-13	67.8
k141_11912_13	SARG|gb|APB03219.1|ARO:3003986|TaeA	23.9	247	320	648	1.25e-09	58.2
k141_11912_13	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	35.2	88	320	461	3.31e-08	53.5
k141_11912_13	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	36.0	75	320	568	1.54e-07	51.6
k141_11912_13	SARG|FR772051.1.gene9.p01	33.3	78	320	524	1.97e-07	51.2
k141_11912_13	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	34.1	88	320	461	2.46e-07	50.8
k141_11912_13	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	22.5	204	320	552	3.57e-07	50.4
k141_11912_13	SARG|gb|AVI44920.1|ARO:3004470|poxtA	25.7	218	320	542	3.45e-06	47.4
k141_11912_17	CARD|gb|AAG05661.1|ARO:3004107|Paer_soxR	36.5	63	257	156	8.96e-07	46.6
k141_45241_7	CARD|gb|AAC76296.1|ARO:3000656|AcrS	43.4	53	220	220	2.29e-06	45.8
k141_45241_9	SARG|gi|921979807|ref|WP_053271336.1|	24.9	201	256	648	6.72e-06	45.8
k141_45241_12	SARG|ABV82118	23.4	667	694	639	3.78e-40	155
k141_45241_12	SARG|ZP_03989103	23.4	667	694	639	3.78e-40	155
k141_45241_12	SARG|ABV82120	23.4	667	694	639	5.09e-40	155
k141_45241_12	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	23.3	664	694	640	5.14e-40	155
k141_45241_12	SARG|FN594949.1.gene24.p01	22.9	664	694	640	5.60e-39	152
k141_15800_5	SARG|gb|AAV85982.1|ARO:3000535|macB	32.8	399	388	644	5.71e-41	152
k141_15800_5	SARG|gi|506220920|ref|WP_015740695.1|	31.5	391	388	647	6.54e-39	146
k141_15800_5	SARG|gi|495067432|ref|WP_007792257.1|	31.7	391	388	647	6.54e-39	146
k141_15800_5	SARG|YP_001438541	31.5	391	388	647	8.94e-39	145
k141_15800_5	SARG|gi|938460528|ref|WP_054624864.1|	31.5	391	388	647	8.94e-39	145
k141_15800_5	SARG|gi|1020141879|ref|WP_063264839.1|	31.5	391	388	647	8.94e-39	145
k141_15800_5	SARG|gi|490522515|ref|WP_004387938.1|	31.5	391	388	647	8.94e-39	145
k141_15800_5	SARG|gi|655997348|ref|WP_029038923.1|	31.5	391	388	647	8.94e-39	145
k141_15800_5	SARG|gi|696420214|ref|WP_032990021.1|	31.5	391	388	647	8.94e-39	145
k141_15800_5	SARG|gi|504542119|ref|WP_014729221.1|	31.5	391	388	647	1.22e-38	145
k141_15800_6	SARG|gi|554685678|ref|WP_023185565.1|	50.9	218	229	648	5.86e-67	216
k141_15800_6	SARG|gi|742378414|ref|WP_038857601.1|	50.9	218	229	647	1.13e-66	216
k141_15800_6	SARG|gi|555222481|ref|WP_023215070.1|	50.9	218	229	648	2.25e-66	215
k141_15800_6	SARG|gi|696402390|ref|WP_032974230.1|	50.9	218	229	647	3.09e-66	214
k141_15800_6	SARG|gi|696423952|ref|WP_032993748.1|	50.9	218	229	647	3.09e-66	214
k141_15800_6	SARG|gi|959866458|ref|WP_058145168.1|	50.5	218	229	648	3.14e-66	214
k141_15800_6	SARG|gi|555246906|ref|WP_023230855.1|	50.5	218	229	648	4.39e-66	214
k141_15800_6	SARG|YP_002044935	50.5	218	229	648	4.39e-66	214
k141_15800_6	SARG|gi|835666879|ref|WP_047606339.1|	50.5	218	229	648	4.39e-66	214
k141_15800_6	SARG|gi|922019548|ref|WP_053299973.1|	50.5	218	229	648	4.39e-66	214
k141_15800_7	SARG|gi|505180395|ref|WP_015367497.1|	28.0	207	310	371	3.04e-12	65.5
k141_15800_7	SARG|gi|851947927|ref|WP_048228599.1|	28.0	207	310	371	3.04e-12	65.5
k141_15800_7	SARG|gi|823311063|ref|WP_047065547.1|	28.0	207	310	371	3.04e-12	65.5
k141_15800_7	SARG|gi|779903737|ref|WP_045374057.1|	28.0	207	310	371	3.04e-12	65.5
k141_15800_7	SARG|gi|779893115|ref|WP_045368519.1|	28.0	207	310	371	3.04e-12	65.5
k141_15800_7	SARG|gi|779948451|ref|WP_045396263.1|	28.0	207	310	371	3.04e-12	65.5
k141_15800_7	SARG|gi|823281239|ref|WP_047037469.1|	28.0	207	310	371	4.09e-12	65.1
k141_15800_7	SARG|gi|895947388|ref|WP_049034529.1|	28.0	207	310	371	4.09e-12	65.1
k141_15800_7	SARG|gi|779925385|ref|WP_045386700.1|	32.2	149	310	371	9.89e-12	63.9
k141_15800_7	SARG|gi|823309641|ref|WP_047064289.1|	32.2	149	310	371	9.89e-12	63.9
k141_15800_9	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.9	219	227	219	2.12e-48	157
k141_15800_9	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.6	225	227	230	2.85e-39	134
k141_15800_9	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.6	225	227	232	4.24e-39	134
k141_15800_9	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.6	225	227	232	4.24e-39	134
k141_15800_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.6	224	227	229	1.10e-38	132
k141_15800_9	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.6	228	227	232	1.68e-38	132
k141_15800_9	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	38.4	219	227	231	3.24e-38	131
k141_15800_9	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	33.6	226	227	231	3.24e-38	131
k141_15800_9	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	37.6	226	227	233	6.79e-38	130
k141_15800_9	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.1	226	227	231	5.06e-37	128
k141_15800_10	CARD|gb|ABD30512.1|ARO:3000839|arlS	36.2	232	456	451	2.03e-34	132
k141_15800_10	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.5	219	456	365	1.18e-17	83.2
k141_15800_32	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	64.7	780	844	1162	0.0	998
k141_15800_32	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	61.0	805	844	1186	0.0	957
k141_15800_32	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	61.0	805	844	1186	0.0	957
k141_67171_23	SARG|gb|AAC74000.1|ARO:3003950|msbA	38.6	399	598	582	1.71e-78	258
k141_67171_23	SARG|gi|662175949|ref|WP_030118884.1|	31.3	597	598	605	3.32e-74	247
k141_67171_23	SARG|gi|505420018|ref|WP_015607120.1|	39.6	386	598	603	8.62e-74	246
k141_67171_23	SARG|gi|663330365|ref|WP_030329892.1|	31.2	597	598	607	9.40e-74	246
k141_67171_23	SARG|gi|501350226|ref|WP_012381861.1|	40.3	385	598	603	1.20e-73	246
k141_67171_23	SARG|gi|490068471|ref|WP_003970646.1|	40.3	385	598	603	1.20e-73	246
k141_67171_23	SARG|gi|664538723|ref|WP_031054357.1|	31.2	597	598	605	1.26e-73	246
k141_67171_23	SARG|gi|663155409|ref|WP_030194633.1|	31.2	597	598	605	1.75e-73	245
k141_67171_23	SARG|gi|926400371|ref|WP_053728483.1|	37.1	428	598	603	3.26e-73	244
k141_67171_23	SARG|gi|517347347|ref|WP_018522839.1|	39.5	385	598	601	4.36e-73	244
k141_67171_27	SARG|gi|507044560|ref|WP_016115614.1|	37.2	199	291	306	1.37e-34	126
k141_67171_27	SARG|gi|446026113|ref|WP_000103968.1|	36.7	199	291	306	3.75e-34	125
k141_67171_27	SARG|gi|500465078|gb|EOP76697.1|	36.4	214	291	306	4.05e-32	119
k141_67171_27	SARG|gi|500448961|gb|EOP61695.1|	36.4	214	291	306	5.66e-32	119
k141_67171_27	SARG|gi|447057510|ref|WP_001134766.1|	37.2	199	291	309	6.01e-32	119
k141_67171_27	SARG|gi|500194536|ref|WP_011867743.1|	35.7	199	291	306	7.89e-32	119
k141_67171_27	SARG|gi|507055561|ref|WP_016126482.1|	37.2	199	291	309	8.38e-32	119
k141_67171_27	SARG|gi|507050365|ref|WP_016121371.1|	37.7	199	291	309	1.17e-31	118
k141_67171_27	SARG|YP_001373621	36.6	202	291	318	1.39e-31	118
k141_67171_27	SARG|gi|447195835|ref|WP_001273091.1|	36.2	199	291	306	1.54e-31	118
k141_67236_2	SARG|gi|489421661|ref|WP_003327389.1|	34.7	101	108	105	8.34e-13	58.5
k141_67236_2	SARG|gi|505052607|ref|WP_015239709.1|	35.5	107	108	112	3.36e-10	52.0
k141_67236_2	SARG|ABS73653	35.5	107	108	112	4.73e-10	51.6
k141_67236_2	SARG|gi|489311091|ref|WP_003218500.1|	31.0	100	108	105	5.76e-10	51.2
k141_67236_2	SARG|gi|489311090|ref|WP_003218499.1|	35.5	107	108	112	6.67e-10	51.2
k141_67236_2	SARG|gi|452079515|emb|CCP21271.1|	35.5	107	108	169	8.96e-10	52.0
k141_67236_2	SARG|gi|1044625135|gb|OCB99622.1|	35.5	107	108	163	1.15e-09	51.6
k141_67236_2	SARG|gi|503879533|ref|WP_014113527.1|	34.6	107	108	112	1.32e-09	50.4
k141_67236_2	SARG|gi|494649292|ref|WP_007407236.1|	34.6	107	108	112	1.32e-09	50.4
k141_67236_2	SARG|gi|489331808|ref|WP_003239065.1|	34.6	107	108	112	1.32e-09	50.4
k141_37606_9	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	33.3	492	505	504	6.51e-79	254
k141_37606_9	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	31.9	496	505	505	2.28e-75	245
k141_37606_9	SARG|AAA50325	28.1	551	505	569	1.52e-35	138
k141_37606_9	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	26.3	494	505	461	3.46e-34	133
k141_37606_9	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	26.2	469	505	461	1.65e-33	131
k141_37606_9	NCBI|AFC62715.1|1|1|eat(A)|eat(A)|target_protection|0|PLEUROMUTILIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Eat(A)|AMR|pleuromutilin	26.0	497	505	500	4.93e-31	124
k141_37606_9	NCBI|WP_000052512.1|1|1|msr(E)|msr(E)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(E)|AMR|multidrug	24.7	511	505	491	9.84e-27	112
k141_37606_9	SARG|gb|AEO25219.1|ARO:3004651|lin	26.2	172	505	523	1.54e-11	65.5
k141_16176_4	SARG|gi|664556405|ref|WP_031071225.1|	34.7	507	597	602	2.26e-58	204
k141_16176_4	SARG|gi|944009777|ref|WP_055601444.1|	34.1	513	597	628	3.40e-57	202
k141_16176_4	SARG|gi|921231571|ref|WP_053176464.1|	34.0	500	597	620	2.07e-56	199
k141_16176_4	SARG|gi|917172177|ref|WP_051778889.1|	34.0	500	597	620	3.94e-56	199
k141_16176_4	SARG|gi|947982677|ref|WP_056642336.1|	33.9	522	597	626	4.34e-56	199
k141_16176_4	SARG|gi|639892676|ref|WP_024755698.1|	33.8	512	597	631	6.48e-56	198
k141_16176_4	SARG|gi|799286378|ref|WP_045936958.1|	33.5	511	597	620	7.50e-56	198
k141_16176_4	SARG|gi|917127754|ref|WP_051734466.1|	33.5	511	597	620	7.50e-56	198
k141_16176_4	SARG|gi|926294973|ref|WP_053631154.1|	33.5	511	597	620	7.50e-56	198
k141_16176_4	SARG|gi|917229923|ref|WP_051836635.1|	33.3	505	597	620	1.04e-55	197
k141_16176_5	SARG|gi|662175949|ref|WP_030118884.1|	30.5	429	582	605	5.69e-43	161
k141_16176_5	SARG|gi|663330365|ref|WP_030329892.1|	30.5	429	582	607	7.95e-43	161
k141_16176_5	SARG|gi|951183771|ref|WP_057661487.1|	30.8	429	582	603	1.93e-42	160
k141_16176_5	SARG|gi|663155409|ref|WP_030194633.1|	30.3	429	582	605	1.97e-42	160
k141_16176_5	SARG|gi|664538723|ref|WP_031054357.1|	30.3	429	582	605	1.97e-42	160
k141_16176_5	SARG|gi|764446018|ref|WP_044369325.1|	30.8	429	582	605	2.69e-42	159
k141_16176_5	SARG|gi|695891735|ref|WP_032792824.1|	30.5	429	582	603	3.59e-42	159
k141_16176_5	SARG|gi|913055317|ref|WP_050357634.1|	30.5	429	582	603	4.89e-42	159
k141_16176_5	SARG|gi|948040364|ref|WP_056699531.1|	30.5	429	582	603	4.89e-42	159
k141_16176_5	SARG|gi|695865802|ref|WP_032778631.1|	30.5	429	582	605	5.00e-42	159
k141_16176_7	SARG|gi|664556405|ref|WP_031071225.1|	33.5	496	580	602	6.28e-68	230
k141_16176_7	SARG|gi|951183771|ref|WP_057661487.1|	33.9	492	580	603	1.73e-67	229
k141_16176_7	SARG|gi|664170108|ref|WP_030704355.1|	33.5	492	580	603	2.40e-67	228
k141_16176_7	SARG|gi|497748188|ref|WP_010062372.1|	33.3	492	580	605	3.48e-67	228
k141_16176_7	SARG|gi|764446018|ref|WP_044369325.1|	33.5	492	580	605	3.48e-67	228
k141_16176_7	SARG|gi|948040364|ref|WP_056699531.1|	33.5	492	580	603	4.66e-67	228
k141_16176_7	SARG|gi|695891735|ref|WP_032792824.1|	33.5	492	580	603	6.48e-67	227
k141_16176_7	SARG|gi|648667297|ref|WP_026359044.1|	33.9	492	580	605	6.74e-67	227
k141_16176_7	SARG|gi|913055317|ref|WP_050357634.1|	33.5	492	580	603	9.01e-67	227
k141_16176_7	SARG|gi|490068471|ref|WP_003970646.1|	33.3	492	580	603	9.01e-67	227
k141_16176_8	SARG|gi|648667297|ref|WP_026359044.1|	52.8	233	610	605	3.50e-65	223
k141_16176_8	SARG|gi|695842130|ref|WP_032755430.1|	51.5	233	610	603	1.72e-63	219
k141_16176_8	SARG|gi|516574297|ref|WP_017949361.1|	49.0	245	610	620	4.56e-63	218
k141_16176_8	SARG|gi|748767925|ref|WP_040019608.1|	50.0	236	610	623	4.82e-63	218
k141_16176_8	SARG|gi|1033217078|gb|OAR27197.1|	51.1	231	610	601	6.13e-63	217
k141_16176_8	SARG|gi|516795764|ref|WP_018105258.1|	51.5	231	610	601	8.50e-63	217
k141_16176_8	SARG|gi|517347347|ref|WP_018522839.1|	51.5	231	610	601	1.64e-62	216
k141_16176_8	SARG|gi|1011969930|ref|WP_062776015.1|	51.1	231	610	601	2.27e-62	216
k141_16176_8	SARG|gi|702897513|ref|WP_033300957.1|	50.6	233	610	601	3.14e-62	215
k141_16176_8	SARG|gi|739906046|ref|WP_037756452.1|	48.6	245	610	620	3.23e-62	216
k141_37722_8	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	34.3	137	401	639	6.22e-14	72.4
k141_54772_6	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.3	317	588	362	9.91e-24	102
k141_54772_6	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.4	288	588	575	8.79e-20	92.0
k141_54772_6	SARG|gi|923061916|ref|WP_053445667.1|	33.8	222	588	648	1.23e-17	85.5
k141_54772_6	SARG|gi|817602846|ref|WP_046596462.1|	33.8	222	588	648	1.63e-17	85.1
k141_54772_6	SARG|gi|554685678|ref|WP_023185565.1|	33.6	226	588	648	2.16e-17	84.7
k141_54772_6	SARG|gi|555268367|ref|WP_023249730.1|	33.3	222	588	648	2.86e-17	84.3
k141_54772_6	SARG|gi|1027935297|ref|WP_063809363.1|	33.3	222	588	648	2.86e-17	84.3
k141_54772_6	SARG|gi|554689873|ref|WP_023186409.1|	33.3	222	588	648	3.78e-17	84.0
k141_54772_6	SARG|gi|446048048|ref|WP_000125903.1|	33.3	222	588	648	3.78e-17	84.0
k141_54772_6	SARG|gi|959109145|ref|WP_058113944.1|	33.3	222	588	648	3.78e-17	84.0
k141_54772_15	SARG|gi|754927849|ref|WP_042284850.1|	41.5	236	234	648	1.02e-51	176
k141_54772_15	SARG|gi|823326845|ref|WP_047080664.1|	42.5	233	234	648	1.02e-50	173
k141_54772_15	SARG|gi|976146774|ref|WP_059305359.1|	42.5	233	234	648	1.02e-50	173
k141_54772_15	SARG|gi|505807117|ref|WP_015704872.1|	42.5	233	234	648	1.02e-50	173
k141_54772_15	SARG|gi|992390012|ref|WP_061077002.1|	43.6	220	234	648	1.02e-50	173
k141_54772_15	SARG|gi|695797094|ref|WP_032711285.1|	42.5	233	234	648	1.02e-50	173
k141_54772_15	SARG|gi|823299155|ref|WP_047054544.1|	42.5	233	234	648	1.02e-50	173
k141_54772_15	SARG|gi|823302270|ref|WP_047057473.1|	42.5	233	234	648	1.96e-50	172
k141_54772_15	SARG|gi|1022664304|ref|WP_063420886.1|	42.5	233	234	648	1.96e-50	172
k141_54772_15	SARG|gi|823309640|ref|WP_047064288.1|	42.5	233	234	648	1.96e-50	172
k141_54772_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.9	231	235	228	4.02e-44	147
k141_54772_16	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.2	233	235	231	1.73e-43	145
k141_54772_16	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	31.6	234	235	232	1.78e-43	145
k141_54772_16	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	31.7	230	235	232	3.55e-43	144
k141_54772_16	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.9	238	235	230	2.66e-42	142
k141_54772_16	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.5	241	235	231	2.73e-42	142
k141_54772_16	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.5	241	235	231	5.44e-42	141
k141_54772_16	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.5	241	235	231	7.67e-42	141
k141_54772_16	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.9	231	235	232	1.11e-41	140
k141_54772_16	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	31.3	240	235	231	3.04e-41	139
k141_54772_29	SARG|AF170880.4.gene1.p01	30.6	219	371	615	4.68e-14	72.4
k141_54772_29	SARG|gi|748767925|ref|WP_040019608.1|	29.3	215	371	623	4.71e-14	72.4
k141_54772_29	SARG|gi|558888514|ref|WP_023543283.1|	30.6	219	371	615	6.24e-14	72.0
k141_54772_29	SARG|gi|754608317|ref|WP_041998010.1|	30.0	217	371	612	4.66e-13	69.3
k141_54772_29	SARG|gi|944009777|ref|WP_055601444.1|	28.1	263	371	628	4.73e-13	69.3
k141_54772_29	SARG|gi|917172177|ref|WP_051778889.1|	28.8	215	371	620	2.62e-12	67.0
k141_54772_29	SARG|gi|919568551|ref|WP_052871170.1|	28.8	215	371	620	2.62e-12	67.0
k141_54772_29	SARG|gi|921231571|ref|WP_053176464.1|	28.8	215	371	620	2.62e-12	67.0
k141_54772_29	SARG|gi|917229923|ref|WP_051836635.1|	28.7	216	371	620	4.65e-12	66.2
k141_54772_29	SARG|gi|926351744|ref|WP_053683383.1|	29.2	216	371	648	4.76e-12	66.2
k141_16355_18	SARG|B7LM76	29.4	177	319	660	1.01e-16	79.7
k141_16355_18	SARG|gi|757781454|ref|WP_043000038.1|	29.9	177	319	660	1.92e-15	75.9
k141_16355_18	SARG|gi|851912779|ref|WP_048215868.1|	29.2	178	319	660	2.70e-14	72.4
k141_16355_18	SARG|gi|1002399350|ref|WP_061382108.1|	27.8	176	319	660	3.62e-14	72.0
k141_16355_18	SARG|gi|696369048|ref|WP_032944060.1|	29.2	178	319	660	4.85e-14	71.6
k141_16355_18	SARG|gi|851965596|ref|WP_048234849.1|	28.1	178	319	660	6.50e-14	71.2
k141_16355_18	SARG|gi|851935911|ref|WP_048224705.1|	27.5	178	319	660	8.71e-14	70.9
k141_16355_18	SARG|gi|507086291|ref|WP_016157032.1|	29.4	163	319	660	8.71e-14	70.9
k141_16355_18	SARG|gi|489931383|ref|WP_003834702.1|	28.5	179	319	660	8.71e-14	70.9
k141_16355_18	SARG|gi|487613526|ref|WP_001735490.1|	28.1	167	319	660	1.17e-13	70.5
k141_16355_27	SARG|gi|772774655|ref|WP_045322518.1|	37.0	316	1177	620	2.62e-42	164
k141_16355_27	SARG|gi|799286378|ref|WP_045936958.1|	34.4	346	1177	620	3.51e-42	163
k141_16355_27	SARG|gi|917127754|ref|WP_051734466.1|	34.4	346	1177	620	3.51e-42	163
k141_16355_27	SARG|gi|764446018|ref|WP_044369325.1|	37.0	332	1177	605	3.89e-42	163
k141_16355_27	SARG|gi|926345639|ref|WP_053677539.1|	34.4	346	1177	620	4.70e-42	163
k141_16355_27	SARG|gi|695865802|ref|WP_032778631.1|	36.4	332	1177	605	6.99e-42	162
k141_16355_27	SARG|gi|926376632|ref|WP_053705806.1|	34.1	346	1177	620	1.13e-41	162
k141_16355_27	SARG|gi|926294973|ref|WP_053631154.1|	34.1	346	1177	620	1.13e-41	162
k141_16355_27	SARG|gi|695887424|ref|WP_032788534.1|	37.7	297	1177	605	1.26e-41	161
k141_16355_27	SARG|gi|497748188|ref|WP_010062372.1|	36.4	332	1177	605	1.26e-41	161
k141_25015_1	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	29.6	240	326	578	4.28e-21	92.8
k141_25015_1	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.1	213	326	307	4.16e-19	85.1
k141_25015_1	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.5	219	326	579	1.32e-17	82.4
k141_25015_1	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.6	219	326	579	1.77e-17	82.0
k141_25015_2	SARG|gi|671541568|ref|WP_031525212.1|	34.6	214	274	648	1.61e-26	107
k141_25015_2	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	28.4	211	274	528	1.43e-12	66.2
k141_25015_2	SARG|gb|NP_388442.1|ARO:3004476|vmlR	25.3	190	274	547	7.58e-07	48.9
k141_59271_3	SARG|gb|AAK76137.1|ARO:3000024|patA	26.9	216	315	564	6.90e-20	89.0
k141_59271_3	SARG|gi|748767925|ref|WP_040019608.1|	30.3	221	315	623	1.34e-19	88.2
k141_59271_3	SARG|gi|739906046|ref|WP_037756452.1|	29.9	221	315	620	1.80e-19	87.8
k141_59271_3	SARG|gi|943938624|ref|WP_055567802.1|	30.8	221	315	602	2.39e-19	87.4
k141_59271_3	SARG|gi|501350226|ref|WP_012381861.1|	29.7	239	315	603	3.22e-19	87.0
k141_59271_3	SARG|gi|926286457|ref|WP_053623344.1|	29.7	229	315	605	3.23e-19	87.0
k141_59271_3	SARG|gi|516574297|ref|WP_017949361.1|	29.4	221	315	620	3.27e-19	87.0
k141_59271_3	SARG|gi|493394434|ref|WP_006350564.1|	28.2	209	315	602	7.86e-19	85.9
k141_59271_3	SARG|gi|662175949|ref|WP_030118884.1|	29.7	229	315	605	7.88e-19	85.9
k141_59271_3	SARG|gi|663155409|ref|WP_030194633.1|	29.7	229	315	605	7.88e-19	85.9
k141_59271_11	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.5	263	661	885	4.32e-19	90.9
k141_59271_11	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.4	262	661	352	4.14e-15	76.3
k141_59271_11	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.4	262	661	376	8.98e-15	75.5
k141_59271_11	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	24.4	262	661	376	8.98e-15	75.5
k141_59271_11	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.4	278	661	364	1.09e-14	75.1
k141_59271_11	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.4	278	661	364	1.09e-14	75.1
k141_59271_11	CARD|gb|AAD51347.1|ARO:3003067|smeS	24.8	266	661	467	4.53e-14	73.9
k141_59271_11	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.0	246	661	361	6.06e-14	72.8
k141_59271_11	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	24.0	246	661	361	6.06e-14	72.8
k141_59271_11	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	24.0	246	661	361	1.08e-13	72.0
k141_63466_50	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.2	755	894	1024	3.02e-61	224
k141_63466_50	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.2	755	894	1024	3.02e-61	224
k141_63466_50	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.2	755	894	1024	5.47e-61	223
k141_63466_50	SARG|gb|CAA53189|ARO:3000521|mupA	24.2	755	894	1024	5.47e-61	223
k141_63466_50	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	25.0	521	894	1107	5.98e-25	110
k141_63466_50	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	25.0	521	894	1107	5.98e-25	110
k141_63466_62	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	54.7	256	276	255	4.31e-95	279
k141_63466_62	SARG|gi|922960663|ref|WP_053388845.1|	41.6	231	276	648	1.46e-48	169
k141_63466_62	SARG|gi|757799695|ref|WP_043016897.1|	41.6	231	276	648	2.80e-48	168
k141_63466_62	SARG|gi|896325272|ref|WP_049294291.1|	38.8	240	276	648	2.80e-48	168
k141_63466_62	SARG|gi|1045891604|ref|WP_065554100.1|	41.1	231	276	648	7.43e-48	167
k141_63466_62	SARG|gi|507082903|ref|WP_016153652.1|	41.1	231	276	648	7.43e-48	167
k141_63466_62	SARG|gi|507086196|ref|WP_016156937.1|	41.1	231	276	648	7.43e-48	167
k141_63466_62	SARG|gi|992380339|ref|WP_061067665.1|	41.5	229	276	648	7.43e-48	167
k141_63466_62	SARG|gi|491270241|ref|WP_005128370.1|	41.5	229	276	648	1.03e-47	167
k141_63466_62	SARG|gi|639225329|ref|WP_024561799.1|	38.2	254	276	648	1.03e-47	167
k141_63466_63	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.1	230	249	228	1.09e-41	141
k141_63466_63	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.2	238	249	231	3.17e-38	132
k141_63466_63	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	38.6	228	249	225	2.11e-37	130
k141_63466_63	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.2	233	249	230	9.47e-37	128
k141_63466_63	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.1	240	249	233	1.44e-36	128
k141_63466_63	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.3	237	249	232	1.98e-36	127
k141_63466_63	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.3	237	249	232	1.98e-36	127
k141_63466_63	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.8	234	249	231	3.82e-36	127
k141_63466_63	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.2	243	249	231	3.82e-36	127
k141_63466_63	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.2	243	249	231	5.37e-36	126
k141_63466_64	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	22.9	245	479	365	6.48e-12	65.9
k141_63466_64	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	20.1	318	479	370	2.70e-09	57.8
k141_63466_64	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	21.7	286	479	392	4.92e-08	53.9
k141_63466_64	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	20.7	347	479	381	1.12e-07	52.8
k141_63466_64	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	20.7	347	479	381	1.12e-07	52.8
k141_63466_64	CARD|gb|CYF42523.1|ARO:3004047|kdpD	22.5	231	479	885	3.09e-07	52.0
k141_63466_64	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	19.9	261	479	380	3.45e-07	51.2
k141_63466_64	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	19.9	261	479	380	3.45e-07	51.2
k141_63466_64	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	20.0	315	479	381	1.07e-06	49.7
k141_63466_64	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	20.0	315	479	381	1.07e-06	49.7
k141_16799_17	SARG|gi|895736250|emb|COF64653.1|	28.6	217	288	309	2.83e-22	93.2
k141_16799_17	SARG|gi|446110087|ref|WP_000187942.1|	28.6	217	288	309	2.83e-22	93.2
k141_16799_17	SARG|gi|445996710|ref|WP_000074565.1|	28.6	217	288	309	2.83e-22	93.2
k141_16799_17	SARG|gi|445996714|ref|WP_000074569.1|	28.6	217	288	309	3.90e-22	92.8
k141_16799_17	SARG|gi|814314593|emb|CKF49145.1|	28.6	217	288	309	3.90e-22	92.8
k141_16799_17	SARG|gi|445996709|ref|WP_000074564.1|	28.6	217	288	309	1.03e-21	91.7
k141_16799_17	SARG|gi|895808656|emb|COR83787.1|	28.1	217	288	309	1.95e-21	90.9
k141_16799_17	SARG|gi|446026113|ref|WP_000103968.1|	27.6	217	288	306	2.58e-21	90.5
k141_16799_17	SARG|gi|507044560|ref|WP_016115614.1|	27.6	217	288	306	6.76e-21	89.4
k141_16799_17	SARG|gi|445996729|ref|WP_000074584.1|	28.1	217	288	309	7.04e-21	89.4
k141_16799_20	SARG|gi|917203192|ref|WP_051809904.1|	36.0	602	677	620	3.01e-97	311
k141_16799_20	SARG|gi|664556405|ref|WP_031071225.1|	34.9	599	677	602	3.71e-97	310
k141_16799_20	SARG|gi|860594225|ref|WP_048475168.1|	36.2	602	677	620	5.91e-97	310
k141_16799_20	SARG|gi|496018010|ref|WP_008742581.1|	35.7	599	677	623	2.46e-96	308
k141_16799_20	SARG|gi|917172177|ref|WP_051778889.1|	36.8	541	677	620	4.48e-96	308
k141_16799_20	SARG|gi|928900436|ref|WP_053931243.1|	36.5	540	677	600	2.03e-95	305
k141_16799_20	SARG|gi|664579989|ref|WP_031094015.1|	36.5	540	677	601	2.08e-95	305
k141_16799_20	SARG|gi|799286378|ref|WP_045936958.1|	35.5	602	677	620	2.42e-95	306
k141_16799_20	SARG|gi|917127754|ref|WP_051734466.1|	35.5	602	677	620	2.42e-95	306
k141_16799_20	SARG|gi|926294973|ref|WP_053631154.1|	35.5	602	677	620	2.42e-95	306
k141_55255_2	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	49.6	353	332	1186	2.16e-108	340
k141_55255_2	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	49.6	353	332	1186	2.16e-108	340
k141_55255_2	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	50.7	343	332	1162	1.64e-104	330
k141_38113_11	SARG|ZP_04433866	54.5	299	312	288	2.88e-110	320
k141_38113_11	SARG|ZP_03984017	54.5	299	312	288	2.88e-110	320
k141_38113_11	SARG|ZP_03949893	53.8	299	312	288	8.22e-110	319
k141_38113_11	SARG|ZP_04528247	53.6	302	312	279	6.59e-102	299
k141_38113_11	SARG|YP_002929946	51.5	305	312	282	3.86e-94	279
k141_38113_11	SARG|ZP_03945515	49.5	301	312	291	7.35e-94	279
k141_38113_11	SARG|ZP_03938934	49.3	300	312	288	1.90e-93	278
k141_38113_11	SARG|ZP_03941859	49.3	300	312	288	2.69e-93	277
k141_38113_11	SARG|ZP_03958019	49.7	316	312	317	5.11e-90	270
k141_38113_11	SARG|YP_002937728	47.1	312	312	289	2.12e-82	249
k141_38113_25	SARG|L42544.gene.p01	27.2	683	706	651	4.80e-74	251
k141_38113_25	SARG|AAV80410	27.2	683	706	651	9.26e-74	250
k141_38113_25	SARG|NP_348076	26.0	693	706	652	9.45e-74	250
k141_38113_25	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	27.2	688	706	641	1.43e-71	244
k141_38113_25	SARG|AAZ79478	27.2	688	706	657	1.97e-71	244
k141_38113_25	SARG|YP_002850805	25.9	683	706	652	2.47e-71	243
k141_38113_25	SARG|Q52360	27.0	688	706	641	3.76e-70	240
k141_38113_25	SARG|Q08425	27.0	688	706	641	1.39e-69	238
k141_38113_25	SARG|P70882	27.0	688	706	641	1.39e-69	238
k141_38113_25	SARG|BAD46890	27.0	688	706	657	1.90e-69	238
k141_38113_30	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	25.1	287	392	337	2.64e-13	69.3
k141_29515_4	SARG|Q83LR7	38.4	224	281	648	7.31e-39	142
k141_29515_4	SARG|gi|647325472|ref|WP_025760953.1|	38.4	224	281	648	7.31e-39	142
k141_29515_4	SARG|gi|647323678|ref|WP_025760497.1|	38.4	224	281	648	7.31e-39	142
k141_29515_4	SARG|gi|446110305|ref|WP_000188160.1|	37.9	224	281	648	2.60e-38	141
k141_29515_4	SARG|gi|446110296|ref|WP_000188151.1|	37.9	224	281	648	1.73e-37	139
k141_29515_4	SARG|gi|486425021|ref|WP_001614493.1|	37.9	224	281	648	2.37e-37	138
k141_29515_4	SARG|gi|446110272|ref|WP_000188127.1|	37.5	224	281	648	3.25e-37	138
k141_29515_4	SARG|gi|486206507|ref|WP_001552670.1|	37.5	224	281	648	3.25e-37	138
k141_29515_4	SARG|gi|1016521294|ref|WP_063100554.1|	37.5	224	281	648	3.25e-37	138
k141_29515_4	SARG|gi|446110307|ref|WP_000188162.1|	37.5	224	281	648	3.25e-37	138
k141_29515_18	SARG|gi|1015784039|gb|KZA89304.1|	28.0	239	398	400	6.24e-16	77.8
k141_29515_18	SARG|gi|446988854|ref|WP_001066110.1|	28.0	239	398	400	6.24e-16	77.8
k141_29515_18	SARG|NC_011595.7060598.p01	28.2	227	398	369	2.38e-14	72.8
k141_29825_7	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	31.1	206	310	357	6.64e-24	99.0
k141_29825_7	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	31.1	206	310	357	6.64e-24	99.0
k141_29825_7	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.5	270	310	354	4.00e-22	94.0
k141_29825_7	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	29.1	268	310	384	1.90e-21	92.4
k141_29825_7	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	29.1	268	310	384	1.90e-21	92.4
k141_29825_7	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.0	240	310	367	3.03e-21	91.7
k141_29825_7	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.0	240	310	368	3.06e-21	91.7
k141_29825_7	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.7	268	310	386	3.61e-21	91.7
k141_29825_7	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	28.7	268	310	386	3.61e-21	91.7
k141_29825_7	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	33.3	204	310	370	1.09e-20	90.1
k141_29825_9	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	38.8	294	307	307	2.49e-70	219
k141_29825_9	SARG|P42332	39.7	300	307	306	1.53e-68	214
k141_29825_9	SARG|ABB80128	39.7	300	307	306	2.17e-68	214
k141_29825_9	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	39.3	300	307	306	4.33e-68	213
k141_29825_9	SARG|gi|510143239|gb|AGN36970.1|	39.3	300	307	313	5.32e-68	213
k141_29825_9	SARG|AAD21213	39.3	300	307	306	2.44e-67	211
k141_29825_9	SARG|gi|507044560|ref|WP_016115614.1|	38.7	300	307	306	3.08e-65	206
k141_29825_9	SARG|gi|446026113|ref|WP_000103968.1|	38.7	300	307	306	6.14e-65	205
k141_29825_9	SARG|gi|507055561|ref|WP_016126482.1|	39.3	303	307	309	6.69e-65	205
k141_29825_9	SARG|gi|488053456|ref|WP_002124853.1|	39.3	303	307	309	9.45e-65	205
k141_29825_10	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.5	232	238	232	1.39e-43	145
k141_29825_10	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	235	238	231	8.43e-42	141
k141_29825_10	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.2	233	238	228	2.18e-41	140
k141_29825_10	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.6	233	238	231	3.71e-40	137
k141_29825_10	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.6	233	238	231	5.22e-40	136
k141_29825_10	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.6	233	238	231	5.22e-40	136
k141_29825_10	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.0	230	238	230	1.01e-39	135
k141_29825_10	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.3	234	238	232	5.94e-39	134
k141_29825_10	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.3	234	238	232	5.94e-39	134
k141_29825_10	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.0	229	238	231	8.15e-39	133
k141_29825_13	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	34.4	320	341	310	2.00e-40	143
k141_29825_13	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	38.5	213	341	308	1.81e-32	122
k141_29873_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.9	223	224	228	8.90e-46	150
k141_29873_6	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.4	225	224	231	2.04e-31	114
k141_29873_6	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.0	225	224	231	1.57e-30	111
k141_29873_6	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.1	225	224	231	3.11e-30	110
k141_29873_6	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	31.1	225	224	231	3.11e-30	110
k141_29873_6	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.1	225	224	231	3.11e-30	110
k141_29873_6	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.6	218	224	229	8.22e-30	109
k141_29873_6	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	30.9	220	224	225	3.60e-26	100
k141_29873_6	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	29.4	221	224	233	8.42e-26	99.4
k141_29873_6	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	31.0	232	224	252	8.92e-26	99.8
k141_29873_8	SARG|gi|742378414|ref|WP_038857601.1|	45.5	222	227	647	7.74e-56	187
k141_29873_8	SARG|gi|981224618|ref|WP_059445588.1|	45.5	222	227	646	1.06e-55	186
k141_29873_8	SARG|gi|836585048|ref|WP_047742322.1|	45.5	222	227	646	1.06e-55	186
k141_29873_8	SARG|gi|1016275448|gb|AMX06027.1|	45.5	222	227	646	1.48e-55	186
k141_29873_8	SARG|gi|779866095|ref|WP_045354445.1|	45.5	222	227	646	2.06e-55	186
k141_29873_8	SARG|gi|779956086|ref|WP_045403603.1|	45.5	222	227	646	2.06e-55	186
k141_29873_8	SARG|gi|823326845|ref|WP_047080664.1|	46.6	219	227	648	2.12e-55	186
k141_29873_8	SARG|gi|746253210|ref|WP_039301529.1|	44.6	222	227	648	2.95e-55	185
k141_29873_8	SARG|gi|695793471|ref|WP_032707680.1|	46.1	219	227	648	4.10e-55	185
k141_29873_8	SARG|gi|505180394|ref|WP_015367496.1|	46.1	219	227	648	4.10e-55	185
k141_50830_19	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	4.92e-97	311
k141_50830_19	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	4.92e-97	311
k141_50830_19	SARG|gb|AKA86814|ARO:3003746|optrA	35.5	504	688	655	4.92e-97	311
k141_50830_19	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	1.35e-96	310
k141_50830_19	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	1.35e-96	310
k141_50830_19	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	1.35e-96	310
k141_50830_19	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	1.89e-96	310
k141_50830_19	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	1.89e-96	310
k141_50830_19	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	1.89e-96	310
k141_50830_19	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.5	504	688	655	2.65e-96	310
k141_50830_29	SARG|gb|APB03216.1|ARO:3003982|LlmA	26.1	180	769	287	3.14e-11	63.9
k141_50830_31	CARD|gb|AAD51347.1|ARO:3003067|smeS	31.5	219	928	467	1.60e-17	85.5
k141_50830_31	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	24.9	213	928	341	3.53e-10	61.6
k141_50830_43	SARG|gb|CAE00499.1|ARO:3003835|cdeA	35.7	434	447	441	9.43e-90	278
k141_50830_77	SARG|gb|AAK76136.1|ARO:3000025|patB	39.1	573	624	588	1.76e-127	387
k141_50830_77	SARG|gb|AYV52072.1|ARO:3002882|lmrD	38.8	513	624	664	4.40e-115	357
k141_50830_77	SARG|gb|CDO61516.1|ARO:3003949|efrB	51.9	337	624	362	8.20e-114	343
k141_50830_77	SARG|gi|944152509|ref|WP_055644808.1|	37.1	510	624	616	1.15e-94	302
k141_50830_77	SARG|gi|944009777|ref|WP_055601444.1|	36.5	509	624	628	3.06e-94	301
k141_50830_77	SARG|gi|695865802|ref|WP_032778631.1|	33.5	600	624	605	4.72e-94	300
k141_50830_77	SARG|gi|947982677|ref|WP_056642336.1|	36.9	510	624	626	1.58e-93	300
k141_50830_77	SARG|gi|639892676|ref|WP_024755698.1|	36.9	510	624	631	1.78e-93	300
k141_50830_77	SARG|gi|695887424|ref|WP_032788534.1|	35.5	518	624	605	1.83e-93	299
k141_50830_77	SARG|gi|764446018|ref|WP_044369325.1|	35.3	518	624	605	3.59e-93	298
k141_50830_78	SARG|gb|WP_104671188.1|ARO:3003948|efrA	41.4	534	721	575	2.36e-121	374
k141_50830_78	SARG|gb|AAK76137.1|ARO:3000024|patA	36.0	520	721	564	3.80e-98	313
k141_50830_78	SARG|gi|501350226|ref|WP_012381861.1|	33.4	371	721	603	1.86e-53	193
k141_50830_78	SARG|gi|505420018|ref|WP_015607120.1|	33.7	371	721	603	4.78e-53	192
k141_50830_78	SARG|gi|695842130|ref|WP_032755430.1|	33.4	371	721	603	6.54e-53	192
k141_50830_78	SARG|gi|948040364|ref|WP_056699531.1|	33.4	371	721	603	8.96e-53	191
k141_50830_78	SARG|gi|664180077|ref|WP_030714054.1|	32.9	371	721	605	9.25e-53	191
k141_50830_78	SARG|gi|664170108|ref|WP_030704355.1|	33.2	371	721	603	1.23e-52	191
k141_50830_78	SARG|gi|490068471|ref|WP_003970646.1|	33.2	371	721	603	1.23e-52	191
k141_50830_78	SARG|gi|951183771|ref|WP_057661487.1|	32.9	371	721	603	1.68e-52	191
